Gene Therapy Approaches To Immune Tolerance Induction In Canine Hemophilia by French, Robert
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
2018
Gene Therapy Approaches To Immune Tolerance
Induction In Canine Hemophilia
Robert French
University of Pennsylvania, robert.french@outlook.com
Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Cell Biology Commons, Immunology and
Infectious Disease Commons, Medical Immunology Commons, and the Molecular Biology
Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2924
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
French, Robert, "Gene Therapy Approaches To Immune Tolerance Induction In Canine Hemophilia" (2018). Publicly Accessible Penn
Dissertations. 2924.
https://repository.upenn.edu/edissertations/2924
Gene Therapy Approaches To Immune Tolerance Induction In Canine
Hemophilia
Abstract
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replacement therapy results in neutralizing
antibodies (“inhibitors”) in ~25% of severe hemophilia A and 1-3% of severe hemophilia B patients. To test
the ability of skeletal muscle-directed gene therapy to prevent an immune response, we used an inhibitor-
prone dog model of severe hemophilia B to express a hyperactive factor IX (FIX) variant from skeletal muscle
via adeno-associated viral (AAV) vector and observed curative levels of expression that lasted for >3 years
(ongoing observation). There was no evidence of an immune response even after immunological challenge
with recombinant FIX protein that would normally provoke high-titer inhibitors in this model. In dogs that
had been previously administered vector, we observed stable expression for >8 years, and immune tolerance
was maintained upon
FIX challenge.
Next, we investigated the ability of liver-directed gene therapy to reverse pre-existing inhibitor responses using
three novel dog models of severe hemophilia A. We expressed canine factor VIII variants with increased
secretion and activity relative to wild-type from
the livers of four dogs by AAV vectors. All dogs had baseline high-titer inhibitors and would have a poor
prognosis with current clinical protocols. One dog died during a spontaneous bleeding event after his
inhibitor titer declined by >90%, but the other dogs completely eradicated their inhibitors and expressed
therapeutic levels of factor VIII at the last sample.
Unlike protein replacement therapy, gene therapy results in stable, constitutive levels of factor. This constant
expression appears crucial to inducing immune tolerance to protein replacement therapy or reversing pre-
existing immune responses. Even in the most
challenging hemophilia models of immune tolerance induction, expression from the vector was able to
prevent an antibody response and induce tolerance to protein replacement therapy or completely eradicate
pre-existing inhibitors in three of four dogs
(one reduced inhibitor titer by >90%). These results support the use of gene therapy to both induce immune
tolerance in high-risk patient populations and provide therapeutic benefit after tolerance is achieved.
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ABSTRACT 
 
GENE THERAPY APPROACHES TO IMMUNE TOLERANCE INDUCTION IN CANINE 
HEMOPHILIA 
Robert A. French 
Valder R. Arruda 
 
A key issue in gene therapy is the immune response to the therapeutic transgene. This 
is especially important in applications where current treatments often elicit an antibody 
response, like hemophilia, where protein replacement therapy results in neutralizing 
antibodies (“inhibitors”) in ~25% of severe hemophilia A and 1-3% of severe hemophilia 
B patients. To test the ability of skeletal muscle-directed gene therapy to prevent an 
immune response, we used an inhibitor-prone dog model of severe hemophilia B to 
express a hyperactive factor IX (FIX) variant from skeletal muscle via adeno-associated 
viral (AAV) vector and observed curative levels of expression that lasted for >3 years 
(ongoing observation). There was no evidence of an immune response even after 
immunological challenge with recombinant FIX protein that would normally provoke high-
titer inhibitors in this model. In dogs that had been previously administered vector, we 
observed stable expression for >8 years, and immune tolerance was maintained upon 
FIX challenge.  
 
Next, we investigated the ability of liver-directed gene therapy to reverse pre-existing 
inhibitor responses using three novel dog models of severe hemophilia A. We expressed 
canine factor VIII variants with increased secretion and activity relative to wild-type from 
the livers of four dogs by AAV vectors. All dogs had baseline high-titer inhibitors and 
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would have a poor prognosis with current clinical protocols. One dog died during a 
spontaneous bleeding event after his inhibitor titer declined by >90%, but the other dogs 
completely eradicated their inhibitors and expressed therapeutic levels of factor VIII at 
the last sample.  
 
Unlike protein replacement therapy, gene therapy results in stable, constitutive levels of 
factor. This constant expression appears crucial to inducing immune tolerance to protein 
replacement therapy or reversing pre-existing immune responses. Even in the most 
challenging hemophilia models of immune tolerance induction, expression from the 
vector was able to prevent an antibody response and induce tolerance to protein 
replacement therapy or completely eradicate pre-existing inhibitors in three of four dogs 
(one reduced inhibitor titer by >90%). These results support the use of gene therapy to 
both induce immune tolerance in high-risk patient populations and provide therapeutic 
benefit after tolerance is achieved. 
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CHAPTER 1 – Introduction 
 
  
 Gene therapy is an expanding field with the potential to treat both inherited 
genetic disorders and environmental or acquired diseases where the introduction of a 
gene product would improve the phenotype. There is significant need for new therapies 
for many inherited genetic disorders and other rare diseases; the NIH and the Global 
Genes advocacy group estimate that approximately 300 million people worldwide are 
affected by the nearly 7,000 diseases that are considered “rare”1,2. In addition, 
approximately 30% of patients with rare diseases die before their fifth birthday3. Many of 
these diseases currently either lack effective long-term therapy or have no therapeutic 
options at all. While therapies for some of these diseases do exist, they often 1) involve 
treatment for the patient’s entire life, 2) are expensive, and 3) may involve complicated 
and intensive pharmacological or surgical regimens in addition to lifestyle limitations. 
Lastly, most current therapies focus on phenotypic amelioration without correcting the 
underlying cause of the disease. Gene therapy, however, offers the potential for long-
term correction of the source of the disease, and consequently, improvement or 
correction of the phenotype.  
 
 Gene therapy can broadly be divided into two categories: in vivo, where genes 
are directly introduced to cells inside the patient’s body, and ex vivo, where cells are 
removed from the patient’s body, receive new genetic material in vitro, and are 
reintroduced to the patient. Both strategies offer distinct advantages and disadvantages, 
and are useful in different disease contexts, as demonstrated by the recent FDA 
approval of both chimeric antigen receptor (CAR) T cell therapies for specific cancers4 
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and Luxturna™ for one form of inherited blindness5, examples of ex vivo and in vivo 
gene therapies, respectively. Regardless of delivery strategy, synthesis of a new protein 
poses the potential risk of an immune response against the transgene product. The risk 
of an immune response against the transgene product is increased if the underlying 
mutation causing the disease phenotype is a frameshift, early stop codon, or a deletion 
of large portions of the gene, as the patient’s immune system is less likely to have 
encountered those protein epitopes via central tolerance6. On the other hand, patients 
with missense mutations or small in-frame deletions have likely been exposed to most of 
the epitopes of the transgene product, and thus have a lower chance of developing an 
immune response. Immune responses against the transgene product could be 
composed of a cytotoxic T cell response and/or a humoral response against a secreted 
or membrane-exposed protein. It is vital that gene therapy not provoke an immune 
response against the therapeutic transgene, especially if the immune response would 
prevent subsequent return to protein replacement therapy or other standards of care. 
 
 There can also be immune responses against the delivery vector. Common 
delivery vectors include viral vectors, like adeno-associated virus (AAV) or lentivirus, as 
well as lipid nanoparticles or even naked plasmid DNA7-10. Different delivery vectors 
carry different risks of provoking an immune response against the vector, which may 
also be affected by delivery method, but can include destruction of targeted cells11 or 
even death12, if immunogenic vectors like adenovirus are used. Consequently, selection 
of an appropriate vector and delivery method is paramount for ensuring the best possible 
safety profile. Within the domain of in vivo gene therapy, the use of AAV vectors is most 
prevalent, due to their low immunogenicity13-16 and efficient transduction of several 
different target tissues, notably the liver, eye, and skeletal muscle17-20.  
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I. AAV-based gene therapy 
 
AAV is a small single-stranded DNA virus first described in 1965 as a 
contaminant of an adenovirus prep21. It is part of the parvovirus family and lacks an 
envelope. Wild-type (WT) AAV has two genes in its genome, rep (replication) and cap 
(capsid), which are flanked by inverted terminal repeats (ITRs) on either side. Both 
genes are necessary but not sufficient for WT AAV replication. AAV is dependent on 
proteins from other viruses to replicate21, which is reflected in its genus name 
(dependovirus). WT AAV will integrate into the human genome in a rep-dependent 
manner, often into a particular region on chromosome 1922,23. Recombinant AAV 
vectors, which lack both rep and cap, do not integrate but exist as episomes in the 
nucleus of transduced cells23.  
 
The fact that AAV vectors do not integrate into the host genome has advantages 
and disadvantages for its gene therapy applications. Lack of integration is associated 
with a more favorable safety profile, as the risk of insertional mutagenesis leading to cell 
transformation and cancer is significantly reduced. However, its episomal state also 
limits its persistence in dividing cells, thus restricting long-term expression from AAV 
vectors to long-lived, post-mitotic cells. Additionally, AAV is not known to cause any 
pathology in humans, despite a fairly high prevalence of seropositivity in the 
population24. Therefore, AAV is an excellent vector platform for many applications, due 
to its lack of integration and insertional mutagenesis, its various serotypes which can 
efficiently target different tissues and cell types, its lack of pathogenicity, and long-term 
expression in post-mitotic cells.  
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While AAV has many advantages, it also has three main limitations. The first two 
constraints are related to the adaptive immune response, while the last limitation is a 
consequence of the small size of the WT AAV genome. First, pre-existing neutralizing 
antibodies (NAbs) can block AAV-based gene transfer13 and the prevalence of NAbs can 
be 40% or higher for some AAV serotypes25. The prevalence of NAbs varies by serotype 
but NAbs to one serotype can cross-react and prevent or inhibit efficient transduction in 
other serotypes as well. These NAbs can also prevent readministration of vector, 
although there is some emerging evidence that transient immunosuppression may be 
able to prevent the formation of NAbs after administration of vector26. Therefore, the high 
prevalence of seropositivity in human populations imposes a limitation on the proportion 
of patients that can be treated with AAV for many applications, especially via systemic 
administration of AAV vector.  
 
The second limitation of AAV is the dose-dependent cytotoxic T cell response 
observed in several clinical trials13,16,27, which occurred despite the use of different AAV 
serotypes. This response is transient, self-limiting, and occurs as vector capsid is being 
cleared by transduced cells13. It has been controllable with a transient course of steroids 
in most, but not all trials28. However, the vector-dose dependency of this response has 
still driven the field to look for ways to improve the efficiency of expression to increase 
efficacy instead of simply raising the vector dose. Interestingly, gene therapy trials 
targeting the eye have not been impacted by the presence of NAbs, even upon repeated 
dosing to treat the contralateral eye, nor have they experienced a cytotoxic T cell 
response14,29,30. This is likely due to the immune-privileged nature of the eye31. In 
addition, preclinical studies using gene therapy targeted to skeletal muscle, either via 
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intramuscular administration or by peripheral transvenular delivery have been less 
sensitive to NAbs32,33. Taken together, this evidence suggests that the target tissue plays 
a substantial role in the degree to which any pre-existing immune response to the vector 
will inhibit transduction, and in the immune response to the vector after gene transfer. 
 
The final major limitation that AAV has is the relatively small packaging capacity; 
with only two genes in the WT AAV genome, the capsid cannot package more than 
approximately 5 kb34, which limits the transgenes, promoters, and enhancers that can be 
used in an AAV vector platform. While there have been some successes in creating 
mini-genes out of genes whose cDNA cannot fit into an AAV, such as dystrophin35,36, this 
approach is not suitable for all genes of interest, as the mini-protein must both be 
effective at a smaller size and avoid provoking an immune response against itself. 
Despite these limitations, AAV has great potential as a vector platform, and is already 
being widely used throughout the drug development pipeline for a range of applications.  
 
II. Hemophilia and the immune system 
 
Hemophilia A and B (HA and HB) are X-linked monogenetic bleeding disorders 
caused by mutations in the F8 and F9 genes, respectively, which code for clotting 
factors VIII and IX (FVIII, FIX). HA is more common, at 1 in 5,000 male births worldwide 
regardless of race, while HB has a prevalence of approximately 1 in 30,000 male births. 
FIX is a serine protease and FVIII is a cofactor for FIX; together, upon activation, they 
form the intrinsic factor X-ase (Xase) complex to activate factor X (FX), the next protein 
in the clotting cascade. Despite being caused by mutations in different genes, HA and 
HB share the same bleeding phenotype and spectrum of clinical severity37. Table 1.1 
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summarizes the phenotypic spectrum; the most severe patients have < 1% residual 
factor activity, and without treatment will spontaneously bleed, often into the joints and 
soft tissues; less common are bleeds into the brain. Importantly, even levels just above 
1% normal factor activity can significantly reduce the frequency of spontaneous 
bleeding, and levels of >5-40% will remove nearly all of the day-to-day symptoms. 
Patients are ideally treated with intravenous prophylactic protein replacement therapy to 
keep factor levels above 1% and prevent spontaneous bleeds. However, this 
replacement therapy is costly (often more than $300,000/year38) and demanding, due to 
fairly short half-lives of both factors39. HA patients often need to administer factor at least 
3x per week or every other day, while HB patients may infuse FIX twice per week. Due 
to cost, many patients in the developing world do not receive prophylactic replacement 
therapy and may not even have access to on-demand therapy during bleeding 
episodes40,41. Plasma-derived and recombinant protein products are available for both 
HA and HB replacement therapy28.  
 
Table 1.1. Hemophilia clinical phenotype spectrum 
Severity 
classification 
Residual factor 
activity (% normal) 
Bleeding type Bleeding 
frequency 
Factor 
replacement 
Severe < 1 Spontaneous Weekly Yes, prophylactic 
Moderate 1 – 5 Some spontaneous Monthly Some 
Mild >5 – 40 With major trauma 
or surgery 
Sporadically On demand 
 
 There is a wide spectrum of underlying mutations in both HA and HB42-45, but 
there are some patterns that emerge. Mild and moderate cases often are due to 
missense mutations or late nonsense or frameshifts, while early nonsense or frameshift 
mutations, large deletions, rearrangements, or inversions often cause severe disease. In 
particular, the intron-22 inversion in the F8 gene accounts for ~40% of severe HA46,47 by 
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itself, and results from a recombination event that ultimately causes an inversion of the 
first 22 exons of F8 (Figure 1.1). Patients without any circulating protein are described 
as cross-reactive material (CRM) negative.  
 
 
Figure 1.1: Schematic of the intron-22 inversion. The intron-22 inversion arises from 
a crossover event between the F8A gene within intron-22 and one of the two additional 
copies of F8A upstream of F8.  
 
 The most significant complication of treatment in hemophilia is the development 
of neutralizing antibodies to the infused clotting factor, called inhibitors. Inhibitor 
responses are polyclonal and in humans typically correlate well with IgG4 titers48-50, 
while inhibitor titers in dogs correlate with IgG251. Inhibitors are typically measured in 
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Bethesda Units (BU), and 1 BU is defined as a sufficient amount of antibody to 
neutralize 50% of the factor activity in normal plasma, agnostic to epitope or mechanism 
of action. Titers less than 0.6 BU are considered inhibitor-negative and are difficult to 
reliably detect. Titers above 5 BU are considered high titer because in the clinic, titers 
above 5 BU preclude treatment with a higher factor dose to overcome the antibodies. 
Titers in between 0.6 BU and 5 BU are low titer inhibitors and can generally be 
overcome with higher or more frequent doses of factor. Individuals who cannot be 
effectively treated with factor replacement are ideally treated with bypassing agents, 
which work through other clotting pathways, like FVIIa or activated prothrombin complex 
concentrates (aPCCs), or more recently alternate pathways entirely, like emicizumab52-56 
or fitusiran57. Unfortunately, bypassing agents typically are both more expensive and 
less effective at preventing or controlling bleeding28,52,58,59 than factor replacement. 
Although newer therapies may be comparably priced or effective at preventing bleeding, 
they are not well suited to on-demand treatment of breakthrough bleeds. In addition, 
some have shorter half-lives and consequently can be more demanding to administer. 
Thus, bypassing agents or alternate hemostatic agents are not the ideal treatment for 
individuals with inhibitors and lead to lower quality of life, more joint damage, and 
possibly shorter lifespans60-64. Therefore, ways to eradicate inhibitors and allow 
treatment with factor again are of considerable importance for treatment of people with 
hemophilia.  
 
Inhibitors develop in approximately 25-30% of severe HA patients and 10% of 
non-severe HA patients, but only 1-3% of individuals with severe HB65-67. Approximately 
half of the patients with inhibitors to FIX develop allergic symptoms to FIX, including 
anaphylaxis in some cases68. It is not currently possible to predict with certainty which 
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individuals will develop inhibitors69-71, but some environmental and genetic risk factors 
have been identified72-75 (Table 1.2). Of those, the largest genetic risk factor is the 
underlying mutation, although other genetic risks factors include a family history of 
inhibitors, non-Caucasian descent, and certain cytokine polymorphisms74,76-83. Patients 
with large gene deletions or early stop codons are most likely to develop inhibitors, while 
those with missense mutations have a fairly low risk84. Interestingly, individuals with an 
intron-22 inversion have a below-average risk of developing inhibitors compared to the 
general pool of people with severe hemophilia A85,86, despite having no detectable 
circulating FVIII protein. Recently, it was discovered that these individuals do make a 
truncated FVIII protein via cryptic exons that fails to secrete, but which nevertheless 
likely contributes to central tolerance and decreases the risk of an immune response87. 
People with severe hemophilia are most likely to develop inhibitors during their first 50 
exposures to factor75.  
 
Table 1.2. Summary of inherited and environmental risk factors for inhibitor 
development in people with hemophilia.  
Patient-related risk factors Treatment-related risk factors 
Severity of underlying F8 or F9 mutation Type of factor product 
Residual FVIII or FIX production Treatment intensity 
Family history of inhibitors First factor exposure 
Race (African-Americans)  
Cytokine polymorphisms (IL-10, TNF-α, 
IFN-γ) 
 
 
The only clinically proven way to eradicate inhibitors is through the immune 
tolerance induction (ITI) protocol. ITI is administered by frequent – often daily or every 
other day – administrations of FVIII or FIX as appropriate, typically at higher doses than 
would be given for hemostasis88-92, sometimes with concurrent immunosuppression in 
people who are refractory to ITI65,93,94, though the evidence supporting this is thin. ITI is 
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successful in approximately 60% of HA cases, depending on the study70,88,90,92 while 
success rates for HB are lower, usually about 30%68. Nephrotic syndrome is a 
recognized complication of ITI in HB95 but not in HA. Studies examining ITI typically 
define success as the following three criteria being met, although the third is only applied 
to ITI for hemophilia A: 1) Negative inhibitor titer (< 0.6 BU), 2) plasma recovery of > 
66% of FVIII or FIX activity after infusion, and 3) FVIII half-life of > 6 hours88. ITI is 
typically followed by protein prophylaxis once tolerance is achieved, as this is believed to 
decrease the risk of relapse. Relapse rates are not widely agreed upon and may range 
between 5-35%58, with the prospective International ITI study reporting 13% relapse at 
year 188. There are some predictive measures of ITI success from retrospective registry 
data96, including historical peak inhibitor titers < 200 BU, titers of < 10 BU at the start of 
ITI, < 2 years between inhibitor diagnosis and initiation of ITI, and age < 8 years old all 
are positive predictors of success88. In the I-ITI study, the median length of time on ITI 
was 14.2 months for the high dose cohort and 16.4 months for the low dose cohort, 
which is in line with other reports70,90,92. Lastly, ITI is very expensive, costing > $1M for 
many patients97,98.   
 
CD4+ T cells are necessary for inhibitor formation and maintenance, as 
demonstrated by reductions in inhibitor titer as their CD4+ T cell count declined99 in 
people with hemophilia who had uncontrolled AIDS. Experimentally, mice show CD4+ T 
cell proliferation during inhibitor development100 and inhibitor development can be 
prevented in mice if CD4+ T cell activation is blocked101, which also decreased pre-
existing inhibitor titer. There is some evidence in mice that marginal zone B cells are 
important for inhibitor formation as well102. As expected, FVIII-specific memory B cells 
and plasma cells (PCs) are formed during the anti-FVIII immune response103. 
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Mechanisms that contribute to ITI success include inhibition of memory B cell 
differentiation by high FVIII concentrations, anergy of effector T cells by overstimulation, 
and induction of regulatory T cells104,105. However, neither the mechanism by which 
inhibitors develop nor the mechanisms by which ITI function is completely understood.  
 
One other significant complication that many older people with hemophilia face is 
the high prevalence of iatrogenic liver disease caused by previously used contaminated 
blood products106. In the 1980s, recombinant protein products were not available, so 
patients received exclusively plasma-derived products107,108, many of which contained 
infectious levels of hepatitis B, C, or HIV. As a result, the prevalence of liver disease in 
people with hemophilia over the age of 35 is substantial and exceeds 80% in some 
areas106. Many of these people have end-stage liver disease or sufficient liver damage 
that they are excluded from liver-directed gene therapy trials due to safety and efficacy 
concerns. Currently, liver-directed gene therapy trials are the only in vivo gene therapy 
trials for hemophilia; thus, these people need alternative gene therapy protocols. One 
attractive alternative target tissue is skeletal muscle, which can produce functional FIX 
protein109 and has been investigated both preclinically and clinically as a target tissue to 
express FIX32,110-114. However, as muscle is less biased towards immune tolerance than 
the liver115,116, the safety and efficacy, particularly the immunogenicity, must be 
thoroughly investigated.  
 
Due to the aforementioned cytotoxic T cell response against AAV capsid at some 
vector doses, the field is interested in increasing expression or hemostatic effect of the 
transgene product while not increasing vector dose. One way to do this that has been 
successful in the clinic16 is to use clotting factor variants that have increased specific 
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activity relative to the wild-type (WT) factor, such as FIX-Padua (R338L) that has been 
shown to have 8-12-fold increased specific activity relative to FIX-WT in both human and 
canine FIX (hFIX and cFIX, respectively)114,117,118. However, one could also use variants 
that secrete more efficiently, such as FVIII+V3119 or FVIII-ΔF120,121. When using a factor 
variant, immunogenicity must be carefully studied, as even minor changes may result in 
loss of immune tolerance. In patients with severe hemophilia and inhibitors, 
administration of a FVIIa variant protein product that differed from FVIIa-WT by three 
amino acids provoked an antibody response in 8 of 72 patients, none of whom were 
FVII-deficient122. Therefore, changes to the amino acid sequence to enhance function or 
secretion must be carefully considered and tested before moving to clinical use.  
 
Inducing peripheral immune tolerance will be crucial for the success of protein or 
gene therapies. There are several cell types that can suppress immune responses in the 
periphery and induce transient or long-lasting immune tolerance, including regulatory T 
cells (Tregs)123, myeloid-derived suppressor cells (MDSCs)124,125, and T regulatory type 1 
(Tr1) cells126 (Figure 1.2). All of these contribute to immune tolerance to self or foreign 
antigens, albeit in different settings and via different mechanisms. T and B cell 
responses can be suppressed directly, where the suppressor cell acts on the T or B cell, 
or indirectly, where the suppressor cell acts upon a different cell that then propagates 
the suppression signal127. Tregs are highly versatile immunosuppressive cells that can 
effectively suppress T cell responses. They exhibit a diverse range of phenotypes and 
use both direct and indirect suppressive mechanisms123. Classical Tregs are defined by 
expression of the surface markers CD4 and CD25 and the transcription factor 
Foxp3128,129. Unlike other T cell subsets, Tregs constitutively express cytotoxic T 
lymphocyte antigen 4 (CTLA-4)130-132, which contributes to indirect suppression of the T 
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cell response by downregulating CD80/86 on dendritic cells133, which are necessary for 
optimal T cell activation134. Tregs can be produced in the thymus (tTregs)135,136 or in the 
periphery (pTregs) from naïve CD4+CD25- T cells in the presence of TGF-β137,138. 
pTregs can directly suppress B cells through TGF-β secretion139. The transcription factor 
Helios is expressed in most, but not all, tTregs, and is not expressed in pTregs140. Within 
the Foxp3 gene, there are three conserved non-coding DNA sequences (CNS1-3) with 
essential functions for Foxp3 expression and stability141. CNS1 is important for 
generation of pTregs, while CNS2 is responsible for maintenance of Foxp3 expression 
and CNS3 increases the frequency of Tregs generated both in the thymus and the 
periphery141.  
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Figure 1.2: Summary of cells that modulate immune responses in the periphery. 
Red boxes are important surface markers; green boxes are cytokines or other molecules 
exported or imported for suppressive effect.  
 
There are several important outstanding questions about the mechanisms of 
Treg-mediated suppression in vivo, including where Tregs exert their suppressive 
activity (lymphoid tissues or target organs) and whether Tregs are constantly required for 
suppression127. However, it is known that a subset of Tregs - follicular regulatory T cells 
(TFR) - traffic to B cell follicles in a CXCR5-dependent manner and work to suppress the 
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differentiation of germinal center (GC) B cells142-144, which they do both through 
interactions with follicular helper T cells (TFH)
145 and direct interactions with B cells146. TFR 
cells require the transcription factor Bcl-6 to express CXCR5142 and under normal 
conditions are generated almost entirely from tTregs142,147. However, under certain 
conditions, mouse antigen-specific TFR cells can also arise from CD4+Foxp3- T cells, 
which is mediated by PD-L1148. Interestingly, Tregs are also important for plasma cell 
(PC) survival in the bone marrow and can regulate the size of the PC pool in the marrow, 
which depends on Treg CTLA-4 expression149. In the bone marrow, both PCs and Tregs 
were observed to interact with CD11c+ dendritic cells, and whether Tregs in the bone 
marrow modulate PCs directly or via interactions with the dendritic cells remains unclear. 
Regardless, Treg induction during ITI has been proposed as one mechanism that could 
contribute to successful immune tolerance induction104,105.  
 
MDSCs are a heterogeneous group of myeloid cells that have failed to fully 
differentiate and mature and have immunoregulatory functions150. MDSCs are expanded 
and activated during pathological conditions, including tumors, infections, autoimmune 
diseases, and organ transplants150,151. They suppress immune responses, especially T 
cell responses, through a variety of mechanisms, including production of NO and 
ROS152,153, elimination of key nutrients for T cell proliferation like L-arginine154 and 
reducing local tryptophan levels by increasing indoleamine 2,3 dioxygenase activity155. 
They can also directly secrete immunosuppressive cytokines like IL-10 and TGF-β156, 
which can contribute to the induction of Tregs157, especially in tumors. However, MDSCs 
are only activated or expanded upon exposure to certain factors, including 
prostaglandins158, IL-6159, and GM-CSF160, which are typically indicative of pathologic 
conditions.  
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Tr1 cells are a unique set of T cells with immunosuppressive properties. Unlike 
classical Tregs, they only transiently express Foxp3 upon activation161,162. Upon antigen-
specific activation through their T cell receptor126,163, they can suppress immune 
responses in an antigen-specific or non-specific manner, mainly via secretion of IL-10 
and TGF-β126,164, and can be identified by the surface markers CD4+CD49b+LAG-3+165. 
Like Foxp3+ Tregs, Tr1 cells express the inhibitory receptor CTLA-4166,167. Tr1 cells can 
also kill myeloid APCs by secreting granzyme B (GzB)163,168, which helps mediate 
bystander suppression of antigens they do not recognize with their T cell receptor. Tr1 
cells have different metabolic requirements than classical Tregs; Tr1 cells depend on 
glycolysis169 while Tregs rely on fatty acid oxidation170. Defects in the frequency or 
function of Tr1 cells is consistently associated with autoimmune and inflammatory 
diseases in both clinical experiences and preclinical models, indicating that they are 
highly relevant for protection against disease171.  
 
There are several potential methods for controlling antigen exposure with the 
hope of inducing immune tolerance. Oral delivery of antigens has been shown to induce 
pTregs172,173. Oral delivery of human (h) FIX to naïve HB dogs with a minimal risk of 
inhibitor formation to canine (c) FIX due to a F9 missense mutation174 resulted in lower 
levels of anti-hFIX IgG2 compared to control dogs, and inhibitor titers were lower or non-
existent175. Additionally, oral delivery of hFIX entirely prevented anaphylactic symptoms 
in treated dogs and completely suppressed IgE formation. Similarly, oral delivery of 
hFVIII to HA mice reduced pre-existing inhibitor titers by ~90%, which was associated 
with an increase in the number of activated (LAP+) CD4+CD25+Foxp3+ Tregs176. 
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In additional to oral antigen delivery, liver-directed gene therapy has been shown 
to induce antigen-specific immune tolerance in several animal models118,177-180. This 
provides two advantages for diseases treated by protein replacement therapy: first, 
inducing immune tolerance makes protein replacement therapy a viable therapeutic 
option again, and second, the gene therapy will provide continuous expression of 
transgene, ideally at therapeutic levels that reduce or remove the need for protein 
prophylaxis. The mechanism behind this peripheral immune tolerance induction in mice 
is generally understood to be dependent on the suppressive activity of Tregs, although 
CD4+ T cell clonal deletion and anergy also play a role177,181-183. Mechanistically, immune 
tolerance to adjuvant-boosted challenge with hFIX could be adoptively transferred in 
C57BL/6 mice only if CD4+ cells were among the transferred splenocytes, and neither 
γδ-T cells nor CD8+ T cells were required177. Later studies showed that hepatic gene 
transfer can induce CD4+CD25+ Tregs capable of suppressing antibody formation to the 
transgene product (hFIX), which could still suppress antibody formation after adoptive 
transfer181. Additionally, adoptive transfer of CD4+CD25+ cells from BALB/c-HA mice 
treated with AAV8-co-hFVIII was able to reduce the anti-hFVIII antibody response in 
recipient mice challenged with hFVIII protein184. Consequently, in mouse models of 
hemophilia, CD4+CD25+ Tregs play an important role in inducing immune tolerance 
after liver-directed gene therapy. 
 
However, the mouse models of inhibitor formation and eradication have several 
shortcomings. First, nearly all murine studies have used human FVIII (hFVIII) or hFIX 
xenoprotein185, and nearly all HA mice will develop inhibitors after repeated exposure to 
hFVIII100, in contrast to the 25-30% of patients with severe HA65-67. In fact, the use of 
xenoprotein can cause inhibitor development in wild-type non-human primates (NHP) 
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expressing hFIX (~20%) or hFVIII (> 50%), which are higher levels compared to human 
replacement therapy186. Murine FVIII protein is difficult to produce and repeated 
injections in HA mice failed to produce a significant antibody response, while a 
comparable injection schedule showed a strong anti-hFVIII antibody response187. Mice 
have been developed that express human HLA-DRB1 * 1501188 due to its potential 
association with higher risk of inhibitor development189,190, but this restricts the available 
MHC presentation library and does not address the issues around administration of 
xenoprotein. There are also strain-specific differences in the immune response and 
tolerance mechanisms in mouse models191,192, the relevance of which to patient 
experiences is unclear. Therefore, there is a need for better animal models of immune 
tolerance induction and inhibitor development.  
 
Studies in large animal models have suggested the involvement of 
Tregs118,180,193. Briefly, we observed immune tolerance induction after liver-directed gene 
transfer in three HA dogs with pre-existing low titer inhibitors180. This was accompanied 
by a transient upregulation of CD4+CD25+Foxp3+ cells in the periphery, suggesting the 
involvement of Tregs in the inhibitor eradication process. In one HB dog with pre-existing 
inhibitors, we observed a cytokine profile characterized by elevated IL-10 and declining 
pro-inflammatory cytokines during tolerance induction, which again suggests the 
involvement of Tregs118,194. Also supporting the contribution of Tregs to the immune 
tolerance induction process after liver-directed gene therapy, depletion of CD25+ cells 
via administration of an anti-CD25 antibody to rhesus macaques concomitant with liver-
directed gene transfer of hFIX resulted in the formation of anti-hFIX antibodies in three of 
three NHP193. In contrast, zero of twelve animals that received similar gene therapy but 
did not receive immunosuppression that altered the frequency of their 
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CD4+CD25+Foxp3+ cells developed anti-hFIX antibodies. Despite these observations, 
the mechanism is still not well understood. This is due to both a lack of high-quality 
antibodies for use in canine immunology studies and the use of human xenoprotein in 
NHP.  
 
III. Dissertation goals 
 
 The goal of this dissertation is to test the hypothesis that continuous, 
uninterrupted transgene expression after gene therapy can induce immune tolerance. I 
use the model diseases hemophilia B and hemophilia A, and outbred large animal 
models, to test this hypothesis. First, in Chapter 2, I examine the safety and efficacy of 
skeletal muscle-directed gene therapy for hemophilia B with a hyperactive cFIX variant 
(R338L) in the most provocative dog model available. Previous work showed safety and 
therapeutic levels of cFIX expression in dogs with a low risk of inhibitor formation, but 
they do not capture the diversity and breadth of the patient population with regards to 
underlying mutation and risk of developing inhibitors. I hypothesized that the continuous 
expression from skeletal muscle would be sufficient to induce and maintain immune 
tolerance to the transgene. Second, in Chapter 3, I test the ability of liver-directed gene 
therapy expressing FVIII variants to eradicate high-titer inhibitors in novel dog models of 
severe HA. I hypothesize that even with a lower vector dose and lower total antigen 
levels, antigen-specific immune tolerance can be induced and therapeutic levels of FVIII 
expression can be obtained after tolerance is achieved. Combined, these results show 
that continuous expression from gene therapy has a striking potential to induce immune 
tolerance to the therapeutic transgene and provide therapeutic levels of transgene 
product afterwards, with a diverse array of possible applications. 
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CHAPTER 2 – Correction of the hemophilia B phenotype and 
immune tolerance induction in inhibitor-prone dogs via skeletal 
muscle gene therapy* 
 
I. Introduction 
 
Hemophilia B (HB) is an X-linked bleeding disease resulting from deficiency of 
coagulation factor IX (FIX) and occurs in approximately 1 in 30,000 male births 
worldwide. Gene therapy is an attractive strategy for hemophilia because modest 
increases in clotting factor levels are associated with phenotypic improvement. Clinical 
trials for HB using adeno-associated viral (AAV) vectors targeting the liver are 
encouraging, and long-term expression of FIX wild-type (WT) transgene product ranges 
from 2% to 7% of the normal range195,196. However, in all AAV liver-directed trials, except 
possibly those using AAV*5, an anti-AAV-capsid cellular CD8+ immune response is a 
limiting safety concern and seems to be vector-dose dependent197,198. Recently, the use 
of liver-directed AAV-FIX-Padua (R338L) resulted in approximately fivefold higher FIX 
activity levels (~30% normal) at a four- to 10-fold lower vector dose16 compared with 
liver-directed AAV clinical trials with FIX-WT195,196, while minimizing the risk of cellular 
immune responses. Transient immunosuppression is effective in controlling the 
complication of anti-AAV capsid CD8+ T cells in most, but not all, studies197,198; 
therefore, avoiding this immune response is an area of active interest to the field. There 
are several ways this response could be mitigated; options being investigated include 
changing the target tissue, using a different AAV vector serotype, or lowering the vector 
dose. Moreover, adult hemophilia patients with underlying iatrogenic viral hepatitis from 
                                               
*
 Some text and figures taken or modified from French, R. A., Samelson-Jones, B. J., Niemeyer, 
G. P., Lothrop, C. D., Merricks, E. P., Nichols, T. C., Arruda, V. R. Complete correction of 
hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog 
model. Blood Advances. 2018;2(5):505-508 
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contaminated blood products106 are ineligible for liver-directed gene therapy due to 
safety and efficacy concerns; thus, alternatives to liver gene therapy are needed.  
 
We have explored AAV delivery to skeletal muscle32,110-114, an ectopic tissue that 
can produce biologically active FIX109. HB dog models have proven to be highly 
informative in regard to the immune responses toward the transgene, as well as vector 
doses needed for therapeutic benefit. We used HB dogs with a minimal risk of inhibitor 
formation to canine (c)FIX resulting from a F9 missense mutation174 from the University 
of North Carolina at Chapel Hill (UNC-CH), to show that direct intramuscular (IM) 
delivery to skeletal muscle of AAV-CMV-cFIX-WT had an excellent safety profile without 
a sustained anti-cFIX immune response110. However, a similar IM injection protocol in 
inhibitor-prone dogs, resulting from an early stop codon F9 mutation199 from the 
University of Alabama at Birmingham (UAB), resulted in the formation of inhibitors to 
cFIX111. These dog models are summarized in Table 2.1. Thus, in the first clinical trial 
evaluating IM injection of AAV-FIX-WT, enrollment was restricted to subjects with 
missense mutations112. Though this therapy did not increase circulating FIX levels, there 
were no safety concerns in HB men. However, the dose in dogs was not scaled up to 
patients by weight or injection sites, due to the dog data that suggested increasing 
vector dose per site above a threshold of approximately 2.0 x 1012 vg/site increased the 
risk of inhibitor formation, and the need to keep the number of injection sites to <90 due 
to limitations in clinical studies.  
 
 
 
22 
 
Table 2.1. Summary of dog models of severe hemophilia B and their inhibitor risk. 
Nomenclature F9 Mutation type Inhibitor risk 
UNC-CH Missense Low: only after muscle 
gene transfer113 
UAB, inhibitor-prone Early stop codon High: after 1 exposure to 
cFIX111 
UAB, University of Alabama; UNC-CH, University of North Carolina at Chapel Hill 
 
 
 Our work in skeletal muscle has predominantly used the cytomegalovirus (CMV) 
promoter/enhancer32,110-114. It has high constitutive activity and thus is suitable to drive 
expression from skeletal muscle. There have been concerns about the use of CMV, as 
in some models and tissues it will shut down over time. However, in the first AAV2-FIX-
WT clinical trial by direct IM injection, local expression of FIX was shown 3.7 and 8 years 
after vector administration, as determined by immunostaining or vector genomes200,201. In 
addition, Glybera, the first gene therapy product approved by the EMA202, used a CMV 
promoter in the skeletal muscle203 and had an excellent safety profile204,205. Lastly, we 
showed durable, stable expression from the CMV promoter in skeletal muscle after 8 
years in two UNC-CH HB dogs206. Indeed, loss of transgene expression due to CMV 
promoter shut down occurs primarily in the liver207,208, and CMV promoter activity is 
stable in the skeletal muscle of dogs and humans without significant loss of expression 
or toxicity.  
 
 Tissue-specific promoters are thought to be safer and potentially more effective, 
due to lower transgene expression in antigen-presenting cells and recruitment of highly 
active tissue-specific transcription factors. Accordingly, we tested two muscle-specific 
promoters (a synthetic c512209, and a muscle creatine kinase, tMCK210) in the skeletal 
muscle of mice. Figure 2.1A shows comparable activity between those two and CMV in 
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mice, which provided the motivation to move to dogs. However, the use of these 
promoters in dogs O23 (c512) and O04 (tMCK) resulted in significantly lower cFIX levels 
than our control dogs that were previously injected with AAV6-CMV-cFIX Padua (Figure 
2.1B, M55 and M59)114. Thus, while none of these dogs developed antibodies to cFIX, 
we continued to use the CMV promoter in our subsequent skeletal muscle experiments.  
 
Figure 2.1: Efficacy of AAV6-canine (c) FIX expression using muscle-specific and 
CMV promoters in mice and dogs. (A) Circulating cFIX antigen levels after gene 
transfer via direct intramuscular injection of AAV6 vector encoding cFIX under the 
control of the indicated promoter to HA-CD4KO mice. tMCK and c512 are muscle-
specific promoters. Bars are means of > 3 samples per mouse (n = 4-6/group) and error 
bars are ± SEM. Pair-wise 2-tail t-test was used to compare results for tMCK and/or 
c512 with CMV within each dose; p > 0.05 considered non-significant (ns). (B) cFIX 
antigen levels in UNC-CH HB dogs after receiving peripheral transvenular delivery of 3 x 
1012 vg/kg of AAV6-cFIX vector under the control of CMV or a muscle-specific promoter.  
 
 Skeletal muscle may not be as biased to immune tolerance as the liver 
is116,118,177. Thus, skeletal muscle-directed gene therapy potentially carries a higher risk 
of an immune response against transgenes compared to liver directed gene therapy. In 
order to test the safety and efficacy of expressing the hyperactive variant cFIX-Padua 
(R338L) from skeletal muscle, we administered 3.0 x 1012 vg/kg of an AAV6 vector 
expressing cFIX-Padua under the control of a CMV promoter (Figure 2.2) to the skeletal 
muscle of three UNC-CH dogs using peripheral transvenular delivery to an isolated 
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limb114. As in our previous studies using this method of administration, a transient course 
of low-dose cyclophosphamide was given around vector administration, as previous 
attempts without immunosuppression resulted in the formation of a transient inhibitor in 
one of two dogs211. These results are summarized in Table 2.2. All dogs converted from 
a severe hemophilia phenotype of less than 1% cFIX activity and spontaneous bleeding 
to a moderate (n = 1, M59) or mild (n = 2, M55 and N07) phenotype, with no 
spontaneous bleeds despite roughly 8 years (n = 2, M55 and M59) or 6.3 years (n = 1, 
N07) of observation time per animal. The expected average bleed frequency in HB dogs 
is 5.5 bleeds/year212; consequently, this is a significant improvement in the clinical 
phenotype in these dogs.  
 
Table 2.2. Summary of results in male UNC-CH hemophilia B dogs after skeletal 
muscle delivery of AAV-cFIX-Padua 
  Plateau cFIX expression   
Dog Age/weight Activity, % Antigen, % Specific activity* Inhibitors 
M55 7 mo/23 kg 8 1.5 8.6 ND 
M59 7 mo/16.5 kg 3.5 0.35 9.2 ND 
N07 6 mo/13 kg 5.5 0.65 9.0 ND 
ND, not detected.  
* mean ratio of activity/antigen at each time point.  
 
The risk of inducing an immune response to the transgene or transduced cells is 
always a concern for gene therapy approaches to hemophilia, and the lack of 
development of inhibitory antibodies to the clotting factor is especially important. To 
rigorously test the immune tolerance to the transgene after vector administration, two 
dogs (M59 and N07) were challenged with normal canine plasma containing cFIX-WT 
once per week for six weeks more than one year after stopping immunosuppression, 
and humoral and cellular immune responses were assayed via the Bethesda assay, 
ELISA for IgG2 against cFIX, and IFN-γ ELISpot. Importantly, the challenges were done 
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with WT cFIX protein in the plasma to mimic the clinical situation, as there are currently 
no human FIX-Padua protein products. Therefore, any patient receiving this gene 
therapy in a clinical setting would, in the event of a bleed or surgery, receive WT hFIX 
products. Accordingly, it is vital that this gene therapy induces immune tolerance not 
only to the expressed transgene, but also the WT protein therapy. No dog mounted a 
detectable immune response; all anti-cFIX IgG2 levels were at or below the background, 
no inhibitory antibodies were detected, and no IFN-γ+ cells were detected upon 
stimulation with AAV6 capsid, cFIX-WT protein, or overlapping peptides covering the 
338 position. Thus, cFIX-Padua shows comparable immunogenicity to cFIX-WT in this 
model, and dogs achieved clinically relevant levels of cFIX activity after gene transfer. 
However, these dogs do not recapitulate the most challenging underlying mutations 
observed in the clinic, such as large gene deletions or early stop codons84. Our next step 
was, therefore, to test this strategy in a more challenging model.  
 
II. Materials and Methods 
 
AAV vector production 
Recombinant AAV serotype 6 vectors were produced by triple transfection as 
previously described110,114 using plasmids for the expression of cFIX-Padua (cFIX-
R338L) under the control of the cytomegalovirus promoter/enhancer, with a human β-
globin intron and the human growth hormone (hGH) poly-A sequence (Figure 2.2).  
 
Canine studies 
 The Institutional Animal Care and Use Committees at the Children’s Hospital of 
Philadelphia (CHOP), University of Alabama-Birmingham (UAB), and University of North 
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Carolina-Chapel Hill (UNC-CH) approved all animal experiments. Two adult inhibitor-
prone female dogs were administered a dose of 3.0 x 1012 vg/kg of the AAV6-CMV-cFIX-
Padua vector, and one adult missense mutation male dog was administered a dose of 
9.0 x 1011 vg/kg of the same vector via the method described below.  
 
Vector administration and transient immunosuppression 
 Transvenular delivery to an isolated limb and transient immunosuppression was 
done as described previously32,114,211,213. A tourniquet was placed atraumatically at groin 
level to temporarily isolate the target limb and the femoral pulse was monitored until no 
longer detectable. A saline solution containing vector was administered using a distal 
catheter (14-18 gauge) under direct visualization into the lumen of a distal branch of the 
peripheral saphenous vein on the dorsum of the paw vein. Vector-containing solution (20 
mL/kg warmed sterile PBS) was delivered rapidly (3 minutes) under elevated hydrostatic 
pressure. This procedure causes local retrograde flow through the valveless venules into 
the capillary beds, ultimately resulting in vector crossing the endothelium into the muscle 
tissue. Immunosuppression consisted of weekly administration of cyclophosphamide at a 
dose of 200 mg/m2 of body surface area starting one week prior to vector administration 
and continuing for a total of 4-6 doses.  
 
Systemic toxicity 
 Complete blood counts, serum chemistries, and liver and kidney function were 
serially monitored as described32. Thrombin-antithrombin levels were measured by using 
the Enzygnost kit (Siemens).  
 
rcFIX-WT protein production 
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 Stable human embryonic kidney 293 cell lines expressing cFIX-WT were 
developed and recombinant cFIX-WT (rcFIX-WT) protein was purified by ion exchange 
chromatography. Dogs were challenged with 0.5 mg of rcFIX-WT intravenously once per 
week for 1-2 weeks.  
 
FIX expression, antibodies to FIX, and coagulation assays 
 The whole blood clotting time, cFIX antigen and activity levels, neutralizing 
antibodies to cFIX (Bethesda assay), and specific anti-cFIX IgG subclasses (IgG1 and 
IgG2) were measured as described32,211. Briefly, cFIX antigen was measured by 
sandwich ELISA (Affinity Biologicals) using pooled normal canine plasma as a reference 
standard, while activity was measured by activated partial thromboplastin time (aPTT). 
Specific anti-cFIX IgG1 and IgG2 were measured by coating rcFIX-WT at 1 μg/mL on an 
ELISA plate, blocked, and serum was used as the primary antibody, while HRP-
conjugated secondary antibodies were used to detect binding.  
 
ELISpot analysis 
 One-color enzyme-linked immunospot (ELISpot) assays were used to measure 
IFN-γ T cell responses to AAV capsid, rcFIX-WT protein, or overlapping peptides 
spanning the 338 site (RATCLR/LSTKFTIYNM, LKVPVDRATCLR/LST)211. Phorbol 
myristate acetate plus ionomycin (PMA + iono) stimulation serves as the positive control.  
 
Anti-AAV6 capsid antibody assays 
 Antibodies to AAV6 capsid were assessed by ELISA118 and neutralizing 
antibodies (NAbs) by an in vivo passive immunization assay adapted for dog samples 
based on previously reported protocols in mice and humans27,214. The passive 
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immunization assay consisted of administration of 50 µL of baseline serum from each 
dog into mice (n =3-4 per group and n=7 for the negative control group) via tail vein 
injection. Positive and negative controls received serum from dogs previously injected 
with AAV6-vectors and PBS, respectively. Three hours after serum or PBS 
administration, an AAV6-cFIX vector at a dose of 2 x 1011 vg/kg was administered by tail 
vein injection and circulating cFIX antigen levels were determined 1 week later by 
ELISA. Transduction efficiency was determined as a percent of the cFIX transgene 
expression levels compared to the negative control.   
 
Vector gene copy number 
 Serum was obtained for the calculation of gene copy number211. Sera were 
treated with DNAse I for 30 minutes at 37°C to eliminate any extra-viral DNA, then copy 
number was assessed by qPCR using an IDT PrimeTime® 5’ 6-FAM™ and 3’ BHQ®-1 
probe in TaqMan® Universal PCR Master Mix. Primers bound the human β-globin intron 
sequence to ensure genomic DNA would not be amplified. Forward primer: 5’-AGC TAC 
AAT CCA GCT ACC AT-3’; reverse primer: 5’-GAG CTG TGG GAG GAA GAT AA-3’; 
probe: 5’-FAM-TGG TTG GGA TAA GGC TGG ATT ATT CTG AGT CC-BHQ-3’. 
Samples were incubated at 95°C for 10 minutes to activate the polymerase and then 
subjected to 40 cycles of PCR. Each cycle consisted of a denaturation step for 15 
seconds at 95°C, an anneal/extend step for one minute at 60°C, and a 20-second step 
at 68°C.  
 
Statistical analysis 
 All statistical analysis was carried out with GraphPad PRISM software, version 7. 
All ANOVA tests are one-way unless otherwise specified.  
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III. Results and Discussion 
 
In the current work, we evaluated the safety and efficacy of expressing cFIX-
Padua from the skeletal muscle of two inhibitor-prone HB dogs from the UAB colony. 
These dogs normally make high-titer (> 5 BU) inhibitors after one administration of cFIX 
protein concentrate111, and thus serve as a model for patients with an elevated risk of 
developing inhibitors due to an early stop codon or large gene deletion84. This inhibitor-
prone model, combined with the relative increased immunogenicity of skeletal muscle-
directed gene therapy compared to liver-directed gene therapy, thus serves as the most 
potent test of the immunogenicity of cFIX-Padua expressed from the skeletal muscle.  
 
We used the same delivery method, immunosuppression regimen, vector dose (3 
x 1012 vg/kg), and regulatory elements (Figure 2.2) as our previous study in the UNC-
CH dogs114. Both dogs (U05 and U04) showed progressive increases in circulating cFIX-
Padua activity after gene transfer, leading to plateau levels of 85 ± 20% and 54 ± 7% of 
normal levels, respectively, where “plateau” is the mean of all time points after day 150 
following gene transfer (Figure 2.3A,B). Therefore, both dogs are in the normal range of 
FIX activity (50 - 150% of normal), making this the first report of curative FIX levels in a 
large animal model after gene transfer to the skeletal muscle. Both dogs normalized their 
whole blood clotting time and exhibited the expected 7- to 10-fold increased specific 
activity of cFIX-Padua compared to cFIX-WT. No local or systemic toxicity was 
observed, and we did not detect abnormal activation of coagulation, as thrombin-
antithrombin complex levels remained in the normal range, nor was there any clinical 
evidence of thrombosis. This agrees with other data in mice, dogs, and humans that FIX-
Padua is not abnormally activated compared to FIX-WT and that total activity levels are 
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likely more predictive of thrombosis risk16,118. Neither dog has had any bleeding episode 
in the cumulative ~6 years of observation time, as would be expected of dogs with 
normal cFIX activity levels. This absence of bleeding, compared to the ~5.5 bleeds/year 
in untreated HB dogs212, shows a substantial improvement in the phenotype of these 
inhibitor-prone dogs.  
 
 
Figure 2.2: Schematic of the viral vector. The canine (c)FIX-Padua (R338L) 
transgene is under the control of the cytomegalovirus (CMV) promoter/enhancer, with a 
human β-globin intron and the human growth hormone (hGH) polyA sequence.  
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Figure 2.3: cFIX activity and antigen levels and cellular immune responses after 
peripheral transvenular delivery of AAV6-cFIX-Padua to skeletal muscle. Two adult 
female inhibitor-prone UAB dogs ([A] U05, [B] U04) were treated with 3 x 1012 vg/kg, and 
one adult male UNC-CH dog ([C], O20) was treated with 9 x 1011 vg/kg of AAV6-cFIX-
Padua. cFIX antigen levels were measured by enzyme-linked immunosorbent assay (■); 
cFIX activity levels were measured by activated partial thromboplastin time (●). * 
indicates the last dose of immunosuppression. Dashed arrows represent treatments with 
normal pooled canine plasma for bleeding; solid arrows represent immunologic 
challenges with recombinant cFIX-WT. (D) Peripheral blood mononuclear cells collected 
28 days after the last protein challenge were analyzed by interferon-γ ELISpot analysis 
after stimulation with AAV6 capsid, cFIX-WT protein, or overlapping peptides spanning 
the 338 region. Phorbol myristate acetate plus ionomycin (PMA + iono) stimulation 
serves as the positive control. Media alone is the negative control. Bars indicate the 
mean of 3 technical replicates and error bars are ± standard error of the mean.  
 
 
Both dogs were challenged with recombinant cFIX-WT protein three times, once 
approximately one year after stopping immunosuppression, and twice (one week apart) 
approximately two years after the first challenge. No antibodies, inhibitory or otherwise, 
were detected in these inhibitor-prone dogs (Figure 2.4A,B), despite the observation 
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that untreated dogs from this colony develop high-titer inhibitors after a single protein 
administration111, thus indicating that skeletal muscle-directed gene therapy with 
transient mild immunosuppression can induce immune tolerance to both the 
endogenously expressed cFIX-Padua and the cFIX-WT protein therapy, which is 
essential for translation to clinical applications. As before, no cellular immune responses 
were detected via IFN-γ ELISpot to AAV6 capsid, cFIX-WT protein, or peptides spanning 
the 338 location (Figure 2.3D). All dogs developed high levels of antibodies to AAV6 
capsid (Figure 2.6B), demonstrating their immunocompetence despite the mild 
immunosuppression around vector administration. Thus, a comprehensive evaluation 
showed no immune response to FIX-Padua in a highly provocative scenario that 
combined the most challenging animal model111 with a target tissue that is not 
predisposed to inducing immune tolerance116.  
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Figure 2.4: Humoral immune responses to canine FIX in HB dogs. Time course of 
neutralizing antibody titers (inhibitors) to cFIX (left-axis) and cFIX-specific 
immunoglobulin levels (right-axis) in U05 (A), U04 (B), and O20 (C) after vector 
administration. Neutralizing antibody titers were determined by Bethesda assay, while 
anti-cFIX IgG1 and IgG2 levels were determined by ELISA. Anti-cFIX IgG1 was 
undetectable in O20 at all time points. Dashed arrows represent treatments with normal 
pooled canine plasma for bleeding, while solid arrows represent immunogenic 
challenges with recombinant cFIX. Dashed line is background IgG1 and IgG2 levels to 
cFIX from WT dogs. 
0 200 400 600 800 1000 1200
0
1
2
3
4
5
0
1000
2000
3000
4000
a
n
ti-c
F
IX
 Ig
G
2
 (n
g
/m
L
)
In
h
ib
ito
r 
(B
U
)
*
cFIX challenge
a
n
ti-c
F
IX
 Ig
G
1
 (n
g
/m
L
)
Time (days)
0 200 400 600 800 1000 1200
0
1
2
3
4
5
0
1000
2000
3000
4000
a
n
ti-c
F
IX
 Ig
G
2
 (n
g
/m
L
)
In
h
ib
ito
r 
(B
U
)
*
cFIX challenge
a
n
ti-c
F
IX
 Ig
G
1
 (n
g
/m
L
)
Time (days)
0 200 400 600 800 1000 1200
0
1
2
3
4
5
0
1000
2000
3000
4000
a
n
ti-c
F
IX
 Ig
G
2
 (n
g
/m
L
)
In
h
ib
it
o
r 
(B
U
)
*
cFIX infusion
Time (days)
A
B
C
U05
U04
O20
34 
 
 
Interestingly, the cFIX-Padua levels in these UAB dogs (U04, U05) are 
significantly higher than the levels observed in the UNC-CH dogs (M55, M59, N07) that 
got the same vector dose, with the same promoter, using the same method of 
administration (Table 2.2)114. We examined pre-existing humoral immunity to AAV6 in 
both cohorts of dogs, as anti-AAV antibodies are known to modulate transduction 
efficiency, and found no difference in AAV6 NAb titer nor in total anti-AAV6 IgG2 levels 
by ELISA (anti-AAV6 IgG1 was undetectable in all cases), as shown in Figure 2.5. Next, 
to verify that the doses were indeed similar, we performed qPCR for vector genomes on 
serum collected two weeks after vector administration, using primers that bound the 
vector’s human β-globin intron sequence, to ensure specificity to the vector. No 
differences in circulating vector genomes within the same dose were found two weeks 
after gene transfer (Figure 2.6A), and importantly we were able to detect a significantly 
lower level of vector genomes in sera with a lower dose of 9 x 1011 vg/kg in one dog 
(O20), indicating that the assay was sensitive enough to at least detect an approximately 
3-fold difference in dose, which would not explain the 8-10-fold difference in circulating 
cFIX activity levels. In addition, the circulating anti-AAV6 IgG2 levels post-vector delivery 
were comparable across all tested dogs (Figure 2.6B); a comparable immune response 
to vector also supports the conclusion that the dose was not significantly different 
between dogs, although it appears to be less sensitive than the serum vector genome 
assay.  
 
The only notable differences between these dogs and the previous dogs, besides 
the underlying F9 mutation, are the sex and leg shape (Table 2.3). The inhibitor-prone 
dogs (U04 and U05) are females, while the UNC-CH dogs (M55, M59, and N07) are all 
35 
 
males; however, while liver-directed gene therapy is less effective in female mice, there 
is no difference in skeletal muscle-directed gene therapy between sexes215. Moreover, 
this sex difference in expression levels would predict a higher level of cFIX-Padua in the 
UNC-CH dogs, contrary to what was observed. The shape of the legs between the two 
dog colonies is substantially different (Figure 2.7), and the large upper thigh of the UNC-
CH dogs likely hinders effective tourniquet placement, possibly leading to less efficient 
vector transduction. Encouragingly, the UAB dogs’ thighs are closer in shape to those of 
a human, supporting the translation of this technique to clinical applications.  
 
Figure 2.5: Antibody titers to AAV6 prior to vector administration. Baseline serum 
prior to gene therapy was evaluated for anti-AAV6 antibodies in all dogs. (A) Serum 
levels of anti-AAV6 IgG2 before vector administration as measured by ELISA. Dashed 
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line is level of pooled NCP (normal canine plasma). There is no statistical difference 
between antibody levels (p > 0.05 as determined by one-way ANOVA). Bars are mean of 
two technical replicates, and error bars are ± SEM. (B) Assessment of transduction 
efficiency after passive immunization in mice. Mice were injected with 50 µL of baseline 
serum samples from HB dogs, followed by infusion of an AAV6-CMV-cFIX vector at 2 x 
1011 vg/kg. Negative control (-ctrl) and positive control (+ctrl) are mice injected with PBS 
or serum from previously AAV6-injected HB dogs, respectively. Circulating cFIX was 
determined 1 week after vector injection by ELISA and transduction efficiency 
determined as percent of the expression levels compared to negative control. Black lines 
indicate the mean and error bars are ± SEM. Each symbol represents the results of a 
mouse. *** Indicates p ≤ 0.001 compared to positive control, as determined by one-way 
ANOVA.  
 
 
 
 
 
 
 
Table 2.3. Baseline clinical and laboratory data comparison of UNC-CH and UAB HB dogs injected with AAV6-cFIX-Padua at 
a dose of 3 x 1012 vg/kg 
 UNC-CH  UAB 
 M55 M59 N07 U04 U05 
Age (mo) 7 7 6 13 17 
Weight (kg) 23 16.5 13 9.4 5.6 
Sex Male Male Male Female Female 
Anti-AAV6 IgG2 (ng/mL) 22 23 40 41 25 
In vivo transduction inhibition 
(%) 
0 12 0 0 0 
Length of follow-up (mo) 101 101 79 37 33 
 
3
7
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Figure 2.6: Serum vector genome copies and humoral response to AAV6 after 
vector administration. (A) Vector genome copy number circulating in serum 15 days 
after vector administration. qPCR primers spanning the CMV promoter-cFIX sequence 
junction were used to determine the number of circulating vector genomes. Bars are the 
mean of three technical replicates and error bars are ± SEM. * Indicates p < 0.05 
compared to O20 as determined by one-way ANOVA. (B) Circulating levels of anti-AAV6 
IgG2 one month after vector administration as measured by ELISA. Bars are the mean 
of two technical replicates and error bars are ± SEM. 
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Figure 2.7: Comparison of the thigh diameters and shape of left rear legs of UAB 
inhibitor-prone and UNC-CH HB dogs. The smaller upper thigh and conical shape of 
the UAB model is likely more conducive to effective tourniquet placement. This model 
also has a shape more similar to a human’s thigh, supporting the translation of this 
technique to patients. The larger upper thigh and cylindrical shape of the UNC-CH model 
likely hinders effective tourniquet use. 
 
One UNC-CH dog (O20) was inadvertently given a subtherapeutic dose of 9 x 
1011 vg/kg (Figures 2.3C and 2.4C) of the same AAV6-CMV-cFIX-Padua vector. This 
resulted in cFIX antigen levels below the limit of detection (~0.3% normal), but sustained 
cFIX activity ~1% normal. Before reaching 1% cFIX activity, O20 had 14 bleeds in 15 
months, but in the 31 months of observation after reaching 1% cFIX activity, he did not 
bleed at all. The complete amelioration of the bleeding phenotype after reaching 1% 
cFIX activity demonstrates the in vivo hemostatic efficacy of FIX-Padua. Despite low 
antigen levels, O20 did not develop antibodies to cFIX-Padua or cFIX-WT, even after 
multiple administrations of canine plasma containing cFIX-WT to treat bleeds. Thus, the 
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potential safety concern observed in mice177 that very low antigen levels favor an anti-
FIX humoral immune response is not supported by the data in this outbred dog. We also 
rechallenged two previously described UNC-CH dogs (M55 and M59) expressing cFIX-
Padua from the skeletal muscle114 with rcFIX-WT protein (Figure 2.8). Despite stopping 
immunosuppression > 8 years prior, neither dog made any detectable immune response 
to cFIX, even though one dog (M55) had not been challenged before, while M59 had 
been challenged with normal canine plasma more than five years prior. These data 
suggest that even minimal levels of continuous, uninterrupted antigen expression, even 
from skeletal muscle gene therapy, are sufficient for sustained immune tolerance.  
 
 
Figure 2.8: Long-term follow-up and additional immunological challenges of UNC-
CH HB dogs that previously received AAV6-cFIX-Padua. Two adult missense 
mutation dogs (M55, [panels A and C] and M59, [panels B and D]) were treated with 3 x 
1012 vg/kg of AAV6-cFIX-Padua by peripheral transvenular delivery to the skeletal 
0 500 1000 1500 2000 2500 3000 3500
0
5
10
15
20
35
50
*
cFIX challenge
c
F
IX
 A
c
tiv
ity
c
F
IX
 A
n
tig
e
n
Time (days)
%
 n
o
rm
a
l 
F
IX
0 500 1000 1500 2000 2500 3000 3500
0
1
2
3
4
5
0
1000
2000
3000
4000
In
h
ib
it
o
r 
(B
U
) an
ti-c
F
IX
 Ig
G
2
 (n
g
/m
L
)
*
cFIX challenge
Time (days)
0 500 1000 1500 2000 2500 3000 3500
0
5
10
15
20
35
50
cFIX challenge
*
c
F
IX
 A
c
tiv
ity
c
F
IX
 A
n
tig
e
n
Time (days)
%
 n
o
rm
a
l F
IX
0 500 1000 1500 2000 2500 3000 3500
0
1
2
3
4
5
0
1000
2000
3000
4000
In
h
ib
ito
r 
(B
U
) an
ti-c
F
IX
 Ig
G
2
 (n
g
/m
L
)
*
cFIX challenge
Time (days)
A
C
B
D
M55 M59
M55 M59
41 
 
muscle as previously published114. cFIX antigen levels were measured by ELISA (■) and 
cFIX activity levels were measured by aPTT (●). Inhibitory antibodies were measured by 
the Bethesda assay and anti-cFIX IgG2 was measured by ELISA. Dashed line is the 
background IgG2 levels to cFIX from WT dogs. * Indicates the last dose of 
immunosuppression. Dashed arrows represent challenges with normal pooled canine 
plasma and solid arrows represent challenges with recombinant cFIX. 
 
Combined, these results narrow the gap between liver-directed and skeletal 
muscle-directed gene therapy in both safety and efficacy. While the skeletal muscle 
gene therapy requires a short course of cyclophosphamide, many liver-directed gene 
therapy trials are requiring a short course of steroids to control an AAV capsid-directed 
CD8+ T cell response. Consequently, both target tissues and methods of delivery 
appear to require immunosuppression, even if the immunosuppressive regimens 
themselves are different. In addition, as skeletal muscle has seen no increased 
immunogenicity upon protein challenge, even in inhibitor-prone dogs that exemplify the 
most challenging clinical scenarios, the transgene safety seems comparable between 
liver and skeletal muscle-directed gene therapy. In terms of efficacy, our lab has 
demonstrated curative levels of cFIX-Padua expression in both liver-directed118 and 
skeletal muscle-directed206 gene therapy in inhibitor-prone HB dogs at the same vector 
dose. Moreover, the intravascular delivery method to the skeletal muscle used in these 
dogs has already been shown to be safe in subjects with muscular dystrophy receiving 
saline alone216 and would be expected to be less safe in already damaged dystrophic 
muscle. From this, we believe the safety profile in HB patients with healthy muscle tissue 
would be excellent. This delivery method may also help AAV vectors avoid some level of 
pre-existing NAb titers, as shown in preclinical models of vector administration and 
prophylactic plasmapheresis32,33. Together, these data provide a strong basis for 
translational studies of FIX-Padua expression from skeletal muscle in HB patients with a 
wide range of underlying F9 mutations, including early stop codons or large gene 
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deletions, who have pre-existing NAb titers to common liver-tropic AAV serotypes and 
low NAb titers to muscle-directed AAVs like AAV6, iatrogenic liver disease, or as a dose-
boost for patients who have already received liver-directed gene therapy.  
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CHAPTER 3 – Eradication of high-titer antibodies to factor VIII in 
novel canine models of hemophilia A via liver gene therapy 
 
I. Introduction 
 
 Hemophilia A (HA) is an X-linked bleeding disorder caused by a deficiency in 
functional factor VIII (FVIII) protein. FVIII is primarily secreted as a heterodimer in 
humans, with the domain structure A1-a1-A2-a2-B-a3-A3-C1-C2217-219 (Figure 3.1). The 
A1-a1-A2-a2-B portion is the heavy chain, which is noncovalently associated with the 
a3-A3-C1-C2 light chain220.  Activated FVIII (FVIIIa) serves as a cofactor for FIXa. FVIIIa 
and FIXa associate in a noncovalent manner on activated membrane surfaces to form 
the intrinsic Xase complex, which is responsible for sustained FX activation during the 
maintenance phase of coagulation221. HA occurs in approximately 1 in 5,000 male births 
worldwide, approximately 60% of which have a severe phenotype and < 1% FVIII 
activity222. HA exhibits the same bleeding phenotype and correlation between residual 
factor activity and severity as HB.  
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Figure 3.1: FVIII domain structure, linkers used in B domain-deleted variants, furin 
processing, and FVIII activation by thrombin. FVIII B domain-deleted constructs use 
the linkers shown to connect the a2 and a3 domains. Underlined amino acids are furin 
cleavage sites within the linkers. Green arrows indicate furin processing sites in wild-
type protein, while red arrows show cleavage by thrombin to activate FVIII to FVIIIa.   
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There are three differences between HA and HB that have made successes in 
HB gene therapy more difficult to translate to HA. First, the incidence of inhibitor 
development to protein replacement therapy is much higher in HA than HB; between 25-
30% of severe HA patients and approximately 10% of non-severe HA patients develop 
inhibitory antibodies to FVIII65-67,223, which cause increased morbidity and mortality224,225. 
Second, the FVIII protein is substantially harder to express and has a shorter plasma 
half-life than the FIX protein226. There appear to be regulatory elements or 
characteristics that reduce FVIII production relative to other proteins of comparable 
size227. In addition, its association in plasma with von Willebrand factor (vWF), which 
also has a short half-life, appears to limit efforts to increase FVIII half-life by adding other 
elements like the Fc region of IgG228. Lastly, F8 is a much larger gene than F9, with a 
complete cDNA of 7 kb219,229, which is outside the ~5 kb packaging capacity of AAV34. 
Fortunately, removal of the B domain, which is not essential for hemostatic function230,231 
and accounts for nearly 40% of the protein232, shortens the cDNA enough to package 
into AAV if a sufficiently short promoter, intron, and polyA sequence are used. Each of 
these has slowed progression towards translation of HA gene therapy to the clinic, but 
there have fortunately been promising results from recent clinical trials233,234.  
 
Inhibitors are more likely to occur in young patients75,78,235,236 but are a growing 
problem for adult HA patients as well237,238. As in HB, both environmental and genetic 
risk factors influence inhibitor formation, and the largest genetic risk factor is the 
underlying F8 mutation. Large gene deletions and early stop codons have the highest 
risk of developing inhibitors239. However, there is considerable heterogeneity in the 
inhibitor response even in patients with the most common mutation that causes severe 
HA (~40% of all severe HA cases46), the intron-22 inversion. There is currently no 
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reliable way to predict with certainty whether an individual patient will develop inhibitors, 
which makes preventative strategies infeasible at present240-242. Inhibitors are measured 
in Bethesda Units (BU), where one BU inhibits 50% of the FVIII activity in normal 
plasma. Inhibitor titers > 5 BU are considered to be high titer inhibitors, and they 
generally prevent effective use of FVIII protein therapy to prevent or control bleeding243. 
When patients develop inhibitors, it is a polyclonal response and it is thought that 
antibodies binding the A2 and C2 domains are a large part of this response244-247, 
although anti-A1, A3, and C1 antibodies have also been reported248-250. Inhibitor patients 
must be treated with expensive alternate therapeutic agents, which have traditionally 
been bypassing agents that act on other parts of the clotting cascade. However, newer 
alternate prophylactic therapies are an area of significant research28. Emicizumab, a 
bispecific antibody that binds FIX(a) and FX(a) to partially mimic FVIIIa function52-56, is of 
particular interest due to its substantially longer half-life than other bypassing agents and 
subcutaneous route of administration. However, emicizumab does have two related 
drawbacks: first, it is not neutralized or regulated by any of the endogenous 
anticoagulants, and second, it is constitutively active. The result of these properties is a 
safety concern about the risk of thrombosis from unregulated activation of coagulation198, 
specifically in the setting of concurrent use with other bypassing agents for the treatment 
of breakthrough bleeds. Despite the new products on the market and in development, 
inducing immune tolerance to FVIII is an area of active clinical research, and is highly 
relevant to clinical care for many patients, as nothing works as well as factor 
replacement to control or prevent bleeding in the absence of inhibitors58. 
  
There is only one strategy currently proven to induce antigen-specific immune 
tolerance to FVIII, which is called the Immune Tolerance Induction (ITI) protocol. ITI was 
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first described when it was observed that frequent administration of large doses of FVIII 
could reduce inhibitor titers over time91. Currently, there are many variations of ITI, but 
they all have in common continuous exposure to FVIII protein via frequent dosing of 
FVIII, often daily administrations of high-dose FVIII88-92. ITI is generally considered to 
have failed if it has not eradicated inhibitors and restored normal FVIII pharmacokinetics 
in the circulation88. It only succeeds in approximately 2/3 of cases70,88,90,92. It is also often 
followed by long-term prophylaxis, as on-demand FVIII therapy is presumed to increase 
the risk of relapse251. ITI is also quite expensive, costing more than $1M/year on 
average97,98, putting it out of reach of many patients in developing countries. Additionally, 
alternate hemostatic agents must be used to control or prevent bleeding until the 
inhibitor titer is low enough to overcome with additional FVIII, which adds to the cost. 
The ITI protocol imposes a substantial burden on patients, especially pediatric patients 
who are the majority of the patient population with inhibitors. Repeated FVIII 
administration often requires a central venous catheter, which adds thrombosis and 
infection risks252,253. While ITI is often successful, there are significant challenges in its 
implementation and these, combined with its expense, are driving research into alternate 
methods of inducing immune tolerance to FVIII.  
 
Low FVIII expression is caused by inefficiencies at several stages, most notably 
by low expression of the mRNA254,255, although improper protein folding leading to 
degradation and inefficient export from the ER to the Golgi also reduce the amount of 
secreted FVIII256,257. Removal of the B domain, which is dispensable for hemostatic 
function, increased mRNA levels 17-fold258; however, secreted FVIII only increased by 
30%, suggesting that the B domain plays a role in transport from the ER to the Golgi. 
Supporting this hypothesis, the B domain contains 19 of the 26 asparagine (N)-linked 
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glycosylation sites on the hFVIII molecule232 and the interaction between those N-linked 
glycosylation sites and lectin mannose binding-1 (LMAN1) protein seems to be important 
for efficient transport to the Golgi227. Various strategies have been employed to increase 
FVIII expression, including codon optimization259,260, adding back portions of the B 
domain to regain some of the N-linked glycosylation sites227 or short synthetic peptides, 
such as the V3 peptide, to add extra glycosylation sites without using long portions of the 
B domain119.  
 
Previously, we observed differences between recombinant B-domain deleted 
cFVIII and hFVIII261; cFVIII is primarily expressed as a single-chain molecule, instead of 
the heterodimer form that dominates in hFVIII. cFVIII has a weaker furin cleavage site at 
the 1645-1648 position, H-H-Q-R instead of the preferred furin cleavage site, R-x-x-R 
(R-H-Q-R in hFVIII). cFVIII also shows higher specific activity and is secreted at higher 
levels compared to hFVIII. We hypothesized that decreasing cleavage by furin would 
increase both the specific activity and secretion of hFVIII. When we changed the furin 
cleavage site in hFVIII to that of cFVIII, we indeed observed a modest increase in both 
activity and secretion262. Next, we removed the furin cleavage site entirely, in both cFVIII 
(cFVIII-ΔF) and hFVIII (hFVIII-ΔF), and observed an approximately 3-fold increase in 
both specific activity and secretion120. Moreover, these advantages were dependent on 
the presence of furin120. To further increase secretion, we inserted the V3 sequence119 
into our cFVIII-ΔF construct to create cFVIII-ΔF+V3. As the field searches for ways to 
increase FVIII expression while keeping vector dose low, modifications that increase 
secretion, activity, or both will be of great interest, as long as they do not increase the 
immunogenicity of the FVIII molecule.  
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AAV vectors are the most used and studied platform for in vivo gene therapy. 
Their safety profile in clinical studies in both adult and pediatric patients has been 
excellent13-16,112,204,205,234,263,264. The first clinical trials using AAV to deliver the FIX gene to 
the liver or skeletal muscle were safe and did not exhibit sustained toxicity13,112,200, and 
the therapeutic doses in canine hemophilia B models were highly predictive of the 
efficacy observed in clinical trials110,265. The use of large animal models for gene therapy 
has been instrumental in translating gene therapy to the clinic212. While mouse models of 
the immune response to gene therapy for hemophilia A have been useful, they do have 
substantial shortcomings. Mice exhibit strain-specific differences in the immune 
response and tolerance mechanisms191,192, and whether these differences are relevant to 
the diverse patient population is not known. Administration of hFVIII protein to HA mice 
results in a strong anti-hFVIII antibody response, but murine FVIII protein failed to result 
in a substantial antibody response on the same injection schedule.187 As a result, hFVIII 
xenoprotein is used in most mouse studies of inhibitor formation and immune tolerance 
induction185. hFVIII induces inhibitor development in nearly all mice100, as opposed to the 
25-30% of people with severe hemophilia A65-67. The endogenous expression of hFVIII 
xenoprotein can result in the formation of inhibitors even in non-human primates186. 
Therefore, large, outbred models that form inhibitors to species-specific FVIII protein, 
such as dogs, are likely more relevant models for the diverse patient population.  
 
The ideal construct for FVIII expression via AAV gene transfer would include a 
small, strong, tissue-specific promoter, an intron to help the mRNA mature, the FVIII 
gene with minimal modifications to enhance secretion and/or function, and a small polyA 
sequence. However, before short, efficient liver-specific promoters were developed, an 
alternate strategy was employed that packaged the FVIII heavy chain (HC) and light 
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chain (LC) into different AAV vectors, with the goal of getting co-transduction of 
hepatocytes and production of the functional heterodimer. This strategy was successfully 
employed to express cFVIII in HA dogs and mice266 and no dogs developed inhibitors to 
cFVIII. Indeed, liver-directed gene therapy has been shown to induce antigen-specific 
tolerance in naïve large animal models, including dogs with severe HA and HB120,212,265-
270.  
 
Reversing an established immune response is more challenging than preventing 
one. Accordingly, we investigated the potential of liver-directed gene therapy to 
eradicate pre-existing inhibitors in HA dogs from two different colonies180. We 
hypothesized that continuous expression of antigen in the anti-inflammatory, tolerogenic 
environment of the liver would idealize the repeated antigen exposure of ITI protocols. 
However, gene therapy would offer three additional advantages: first, a single 
administration of vector could replace daily injections of FVIII and potentially avoid the 
placement of a central line; second, once administered, the vector would be continually 
expressing FVIII and would not have the potential complication of thrombosis or infection 
in the central line, which often necessitates pausing ITI and has negative consequences 
for success; and third, after the inhibitors were eradicated, the expression from the 
vector would provide long-term therapeutic levels of FVIII, thus eliminating or reducing 
spontaneous bleeding events and providing, in essence, simplified lifelong prophylaxis.  
 
Finn et al. showed the proof-of-concept for this strategy by tolerizing four HA 
dogs from two different colonies with pre-existing inhibitors to cFVIII in an antigen-
specific manner180. These dog models have circulating FVIII antigen and activity levels < 
1% of normal and recapitulate the spontaneous bleeding phenotype observed in severe 
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HA patients. The underlying causative mutation in both colonies271,272 is an intron-22 
inversion, which accounts for ~40% of severe disease in humans47. Three of the four 
dogs come from a group within the University of North Carolina-Chapel Hill (UNC-CH) 
colony that develops anti-cFVIII antibodies upon exposure to normal canine plasma 
(containing cFVIII protein)212. The fourth dog was from the colony at Queen’s University 
in Canada, which has a high risk of inhibitor development upon exposure to cFVIII 
protein and was actually treated with hFVIII prior to enrollment in that study. The use of 
two outbred dog colonies more accurately recapitulates the varied genetic backgrounds 
and immunologic risk observed in patients and thus served as an excellent model for a 
proof-of-concept study for inducing immune tolerance via liver-directed AAV-based gene 
therapy.  
 
These dogs were administered 2.5 x 1013 vg/kg of an AAV8 vector expressing 
the cFVIII HC under the control of a liver-specific promoter (human thyroxine binding 
globulin, TBG), and the same dose of an AAV8 vector expressing the cFVIII LC (total 
vector dose 5.0 x 1013 vg/kg), also under control of the TBG promoter. Table 3.1 shows 
the clinical characteristics of these dogs, while the eradication of inhibitors in the UNC-
CH dogs is summarized in Figure 3.2. The three UNC-CH dogs all eradicated their 
inhibitors within 4-5 weeks after vector administration and had peak titers after vector 
administration of < 10 BU. An inverse relationship was observed between cFVIII levels 
and inhibitor titer. As expected from the dual-chain vector system, cFVIII LC antigen 
levels were 5-10-fold higher than cFVIII activity and HC antigen levels266. Once cFVIII 
levels stabilized in the UNC-CH dogs, generally between 50-150 days after vector 
administration, these dogs were challenged with four weekly injections of rcFVIII to 
confirm immune tolerance to cFVIII. During and after challenges, there was no evidence 
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of antibodies, inhibitory or otherwise, to cFVIII, and levels remained stable for more than 
3 years after challenge. In two dogs, rcFVIII was infused to measure recovery and 
exclude the possibility of non-neutralizing antibodies that might increase clearance of 
cFVIII. Excellent recovery was observed in both dogs. Lastly, all dogs mounted a strong 
antibody response against the AAV8 vector capsid after vector administration and did 
not show any clinical signs of general immunosuppression such as predisposition to 
infections, supporting the hypothesis that the induced immune tolerance is antigen-
specific. Interestingly, the cFVIII levels in K03 (Figure 3.2C) were significantly higher 
than those of K01 and L44 (Figure 3.2A,E). The reason for this is unknown; however, 
K03 received a transfusion of normal canine plasma at the time of vector administration 
to control bleeding from a jugular puncture wound incurred when baseline samples were 
collected, while K01 and L44 did not receive plasma. We previously showed that 
correcting hemostasis before delivery of an AAV2 vector improved transduction in 
murine models273, and it is possible that correcting hemostasis in K03 via plasma 
infusion resulted in more efficient vector transduction despite the circulating low-titer 
inhibitors.  
  
 
 
Table 3.1. Summary of inhibitor eradication in UNC-CH and QU hemophilia A dogs following cFVIII LC and HC chain 
expression by separate AAV8 vectors 
   Inhibitors  Bleeds over time, mo 
Dog Age, yr Weight, kg Duration before 
treatment, mo 
Historical 
peak, BU 
Time to 
eradication, wk 
cFVIII plateau 
activity, % 
Pretreatment Posttreatment 
K01 1.7 20.1 8 12 5 1.5 3/20 2/121 
K03 1 19.3 7 12 4 8.0 7/12 4/126 
L44 0.7 16.0 4 4.5 4 1.5 5/8 6/116 
Wembley 4.9 16.5 24 3.6 80 6.2 - - 
Total       15/40 12/363 
-, not available
5
3
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Figure 3.2: cFVIII expression and anti-cFVIII antibody responses in UNC-CH dogs 
K01, K03, and L44 after liver delivery of AAV8-TBG-cFVIII. Three UNC-CH dogs (K01 
[A, B], K03 [C, D], and L44 [E, F]) with pre-existing inhibitors to cFVIII were administered 
2.5 x 1013 vg/kg of each of AAV8-TBG-cFVIII LC and AAV8-TBG-cFVIII-HC by 
peripheral venous injection. (A, C, E) cFVIII LC antigen levels were measured by a 
cFVIII LC-specific ELISA, and activity was monitored by FVIII assay. (B, D, F) Anti-cFVIII 
antibody responses were measured by anti-cFVIII IgG2 ELISA and Bethesda assays. 
Black arrows indicate 4 weekly challenges with ~25 U/kg of rcFVIII-BDD.  
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The dog from Queen’s University (Wembley) exhibited different kinetics in his 
response to vector administration (Figure 3.3B). Specifically, his anti-cFVIII inhibitor titer 
went from 3.5 BU at the time of vector administration to a peak of approximately 217 BU 
two weeks later. It took 550 days for his inhibitor titer to drop below 0.6 BU, which is 
generally considered to be the cutoff for a negative inhibitor. The reason for the 
discrepancy in anamnestic response between Wembley and the UNC-CH dogs is 
unknown; however, it may be related to his prior exposure to xenoprotein, or simply due 
to the differences between different strains of dogs. At the time of publication, Wembley 
had detectable circulating cFVIII LC antigen, but cFVIII activity was < 1% normal. 
Interestingly, his inhibitor titer to hFVIII, the xenoprotein he was initially exposed to, rose 
from a baseline of 7.4 BU to a peak of 271 BU before declining over time. When his anti-
cFVIII dropped below 0.6 BU, his anti-hFVIII inhibitor titer remained at 2.2 BU (Figure 
3.3C). A similar pattern was observed in his anti-hFVIII IgG2 levels. Together, these 
results indicate that his immune tolerance induction was specific to cFVIII.  
 
While these results were impressive, only one dog had sustained high titer 
inhibitors, and none had an underlying mutation with the highest likelihood of inhibitor 
formation. In addition, it was unclear whether the modified FVIII molecules would be able 
to induce immune tolerance with lower vector doses, although cFVIII-ΔF was well-
tolerated in two naïve HA dogs120. In fact, when we combined the cFVIII-ΔF gene variant 
with a smaller liver-specific promoter based on the human alpha-1-antitrypsin (hAAT) 
promoter and an apolipoprotein E (ApoE) enhancer (referred to in combination simply as 
hAAT), we were able to package the entire FVIII cassette into a single AAV vector and 
achieve comparable expression levels in two HA dogs while reducing vector dose from a 
total of 5.0 x 1013 vg/kg to 6.0 x 1012 vg/kg, a nearly 10-fold lower dose120. Here, we set 
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out to test the safety and efficacy of inducing immune tolerance in new dog models with 
high titer inhibitors and novel underlying mutations or genetic backgrounds via liver-
directed AAV gene therapy expressing new FVIII variants. We start probing the open 
question of the role of antigen levels on the kinetics of immune tolerance induction, and 
we begin to investigate the epitope diversity of the antibody response to cFVIII in one 
novel model to support the relevance of this model to clinical experiences.  
 
II. Materials and Methods 
 
AAV vector production 
 Recombinant AAV8 vectors were produced by triple transfection as previously 
described13, using plasmids encoding cFVIII-ΔF or cFVIII-ΔF+V3 under the control of the 
human alpha-1-antitrypsin (hAAT) promoter and an apolipoprotein E (ApoE) enhancer 
element.  
 
Animal experiments 
 All animal experiments were approved by the Institutional Animal Care and Use 
Committees at the University of Pennsylvania, the Children’s Hospital of Philadelphia, 
and the University of North Carolina at Chapel Hill. Two adult male dogs with pre-
existing inhibitors to cFVIII were administered 6.0 x 1012 vg/kg of an AAV8-hAAT-cFVIII-
ΔF vector (Loxley, Noah) intravenously via the saphenous vein. Prior to vector infusion, 
Loxley received 320 U rcFVIII-ΔF and Noah received 100cc normal pooled canine 
plasma. Two adult male dogs with pre-existing inhibitors to cFVIII were administered 9.0 
x 1012 vg/kg of an AAV8-hAAT-cFVIII-ΔF+V3 vector (T01, T02) intravenously via the 
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saphenous vein. Both T01 and T02 received approximately 100cc FVIII-deficient pooled 
canine plasma prior to vector infusion.  
 
Systemic and local toxicology 
 Complete blood counts, serum chemistries, and liver and kidney function were 
serially monitored32,267,270.  
 
Canine FVIII antigen, activity, and antibody assays 
 The whole blood clotting time (WBCT) was performed as previously described261. 
cFVIII activity was quantitated by Chromogenix Coatest SP4 FVIII (Diapharma, 
Lexington, MA), and pooled normal canine plasma was used as the standard. cFVIII LC 
antigen levels were measured by capture ELISA using the 2C4.1C3 clone as previously 
described261 or by cFVIII ELISA kit (Affinity Biologicals). Anti-cFVIII antibodies were 
measured by Bethesda assay or by cFVIII-specific IgG ELISA as previously 
described261.  
 
Canine FVIII epitope mapping 
 Antibodies to specific epitopes of cFVIII were detected by ELISA. Peptide pools 
were created from a library of 15-mers overlapping by 10 amino acids with the previous 
peptide (Mimotopes). Pools were assigned in a matrix format and coated in duplicate on 
a 96-well plate. Uncoated wells served as a negative control and rcFVIII-BDD protein at 
1 µg/mL served as a positive control. Wells were blocked with Low Cross buffer 
(CANDOR Bioscience GmbH, Germany) at 22°C for 1.5-2h and washed 3 times in PBS-
0.05% Tween-20. Samples diluted in Low Cross buffer were then incubated on the plate 
for 2h at 22°C. Antibody was detected as the anti-cFVIII IgG1 or IgG2 ELISAs, via HRP-
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conjugated secondary antibodies261. Pools were considered positive if the mean OD of 
the duplicate wells was at least 1.5 times the OD of the negative control. Pools between 
1.25 and 1.5 times the negative control OD were retested and if they were still not 
positive, were considered negative. Each peptide from positive pools was tested 
individually and evaluated in the same manner.  
 
Data analysis 
 All data analysis was carried out using the GraphPad Prism 7 software. Curve fits 
for inhibitor titer were generated as a one-phase exponential decay with the plateau 
value set to 0.  
 
III. Results 
 
Long-term follow-up of one dog from Queen's University 
Wembley was unique in our original proof-of-concept paper describing immune 
tolerance induction in severe HA dogs with pre-existing inhibitors, due to his exposure to 
hFVIII xenoprotein, large anamnestic response, and substantially longer time to inhibitor 
eradication180. Long-term follow-up confirmed that, as hypothesized, his cFVIII LC 
antigen and activity rose (Figure 3.3A) as his anti-cFVIII IgG2 levels continued to 
decline (Figure 3.3B). Ultimately, his cFVIII LC antigen and activity levels reached a 
plateau of 74 ng/mL and 6.2%, respectively. To confirm his immune tolerance to cFVIII, 
we challenged him more than six years after vector administration with four weekly 
administrations of rcFVIII protein, and neither his inhibitor titer nor his anti-cFVIII IgG2 
levels rose above the cutoff for a positive response. His therapeutic levels of cFVIII, 
6.2% normal activity (Figure 3.3A), did not change before and after challenges, which 
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indicates immune tolerance to both the expressed transgene and the infused protein. 
Interestingly, as Figure 3.3C shows, his inhibitor titer against hFVIII, which he was 
initially exposed to, remained for much longer than his inhibitor to cFVIII, indicating that 
he was being specifically tolerized to epitopes in cFVIII. In fact, his IgG2 antibody 
response to hFVIII never dropped below the cutoff, despite not having been exposed to 
hFVIII for more than six years. We did not challenge him with hFVIII after this, because it 
would not recapitulate the clinical experience in patients, as they would not be treated 
with FVIII from a different species in the absence of inhibitors. While it would be an 
interesting experiment, if any of his inhibitors to hFVIII cross-reacted with the 
endogenous cFVIII, this could complicate his clinical care.  
 
Figure 3.3: cFVIII expression and antibody responses against cFVIII and hFVIII in a 
high-responding dog from Queen’s University after AAV8-mediated expression of 
cFVIII LC and HC from separate vectors. One hemophilia A dog from Queen’s 
University (Wembley) with pre-existing inhibitors to hFVIII that cross-reacted with cFVIII 
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was administered 2.5 x 1013 vg/kg each of AAV8-TBG-cFVIII LC and AAV8-TBG-cFVIII 
HC by peripheral venous injection. (A) cFVIII LC antigen levels were measured by a 
cFVIII LC-specific ELISA, and activity was monitored by FVIII assay. (B) Anti-cFVIII 
antibody responses were measured by anti-cFVIII IgG2 ELISA and Bethesda assays. 
(C) Anti-hFVIII antibody responses were measured by anti-hFVIII IgG2 ELISA and 
Bethesda assays. Black arrows indicate 4 weekly challenges with rcFVIII-BDD. 
  
 
Approach to examining the impact of improved FVIII variants and antigen levels 
on immune tolerance induction 
 We report here the safety and efficacy of antigen-specific immune tolerance 
induction via liver-directed gene therapy expressing cFVIII variants in novel dog models 
of severe HA with high titer pre-existing inhibitors. These three models have not been 
previously described. They are all genetically unrelated to existing dog models of severe 
HA and each other. Consequently, they display different anti-cFVIII immune response 
characteristics. Our novel models are summarized in Table 3.2. We set out to address 
two important questions about the use of liver-directed gene therapy to induce immune 
tolerance in hemophilia A: 1) would modifications to the FVIII protein that increase 
biological activity or secretion be able to induce immune tolerance in dogs with pre-
existing high-titer inhibitors, and 2) how do antigen levels affect the kinetics of immune 
tolerance induction.  
 
 To probe these questions, we divided our dogs into low and high vector dose 
cohorts. Our low antigen cohort received an AAV8 vector expressing our cFVIII-ΔF 
variant at 6.0 x 1012 vg/kg, which was therapeutic in naïve HA dogs120. For a higher 
antigen level, we both raised our AAV8 vector dose to 9 x 1012 vg/kg and combined the 
V3 peptide, which increases secretion, probably by adding glycosylation sites119, with our 
ΔF variant120 to create cFVIII-ΔF+V3. As the ΔF change and the V3 peptide increase 
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secretion through different mechanisms, and the V3 peptide does not affect specific 
activity, we hypothesized that these modifications would not exhibit negative synergy, 
and data in HA mice supported this hypothesis (Figure 3.4).  
 
Table 3.2. Summary of liver-directed AAV8 gene therapy for immune tolerance 
induction in novel dog models of severe hemophilia A, prior to gene therapy. 
  Inhibitor titer (BU)   
Model F8 mutation Baseline  Peak Vector dose 
(vg/kg) 
cFVIII variant 
Noah 
~25kb 
deletion 
598 774 6.0 x 1012 cFVIII-ΔF 
Loxley 
Intron-22 
inversion 
21 46 6.0 x 1012 cFVIII-ΔF 
Texas trio 
T01  
T02 
T03 
Intron-22 
inversion 
 
107 
89 
154 
 
107 
182 
154 
 
9.0 x 1012 
9.0 x 1012 
untreated 
cFVIII-ΔF+V3 
cFVIII-ΔF+V3 
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Figure 3.4: Expression of different cFVIII variants in HA-CD4KO mice after AAV8 
gene transfer. HA-CD4KO mice were administered 4 x 1011 vg/kg of AAV8-hAAT-
cFVIII-variant vector via tail vein injection. Plasma was collected 4 weeks after vector 
administration and antigen levels were determined by cFVIII-HC-specific ELISA. co, 
codon-optimized.  
 
Novel dog models of severe HA 
Model 1: Noah 
The first novel model was originally a privately-owned dog that was treated with 
plasma for bleeding episodes and subsequently developed a high titer inhibitor. Due to 
expense of treatment, the owner then donated the dog, Noah, to the colony at UNC-CH. 
Subsequent genetic testing revealed a large gene deletion in the F8 gene, covering 
approximately 24.7 kb from intron-21 to part of intron-25, combined with a 57 bp 
insertion (Figure 3.5). As expected, this dog had < 1% circulating cFVIII activity and 
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antigen. Excitingly, large gene deletions have a very high risk of inhibitor formation, and 
since his arrival at the colony, Noah had some puppies, including three female carriers, 
allowing us to expand this novel model with a high risk of inhibitor formation.  
 
 
Figure 3.5: Schematic of Noah's novel underlying F8 mutation resulting in severe 
hemophilia A. Black, F8 exons and blue, F8 introns. Red dashed arrow indicates span 
of deletion. 
 
 At arrival to the dog colony Noah had an inhibitor titer of > 400 BU, which was not 
only higher than any previous dog tested, but was also above the 200 BU threshold 
associated with negative ITI success88. This very high titer, combined with his underlying 
mutation, result in what would be the worst-case situation in a clinical setting. Noah 
received 6.0 x 1012 vg/kg of an AAV8 vector expressing cFVIII-ΔF under the control of 
the hAAT promoter/ApoE enhancer. We administered 100cc normal canine pooled 
plasma prior to vector administration, as our prior experiences suggested better vector 
transduction when coagulation proteins were present even with inhibitors in the 
circulation180. At vector administration, Noah’s inhibitor titer was 598 BU (Figure 3.6A), 
the highest baseline inhibitor titer we have treated to date. He quickly had an anamnestic 
response, likely to the infused protein, as his inhibitor titer climbed to 774 BU two days 
after vector administration. Expression from the vector was confirmed by detection of 
approximately 3 ng/mL of cFVIII via ELISA at day 7 post-vector (Figure 3.6B), at the 
same time as the inhibitor titer dropped to approximately 26 BU. cFVIII activity never 
rose above 1% throughout the observation period, and cFVIII antigen was undetectable 
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after day 15, likely due to rapid antibody-mediated removal of cFVIII from circulation. His 
titer quickly rebounded to 397 BU at day 15, and continued to climb until day 36, after 
which it resumed its decline. Results looked encouraging until he had a severe bleeding 
episode into his chest cavity at day 121 that required treatment with rcFVIIa, rhFVIIa, 
rcFVIII, whole blood, and anti-fibrinolytic agents. During this time, his inhibitor appeared 
to drop to 91 BU, but then rebounded to 745 BU, likely due to exposure to exogenous 
cFVIII. Following this, his bleeding episodes were less severe and his inhibitor titer and 
anti-cFVIII IgG levels dropped steadily, until day 602 when he had an intussusception 
requiring surgery. Here, he received the bypassing agents hFVIIa and cFXa I16L, whole 
blood, and more anti-fibrinolytic agents. Encouragingly, he did not mount a strong 
anamnestic response after exposure to the whole blood, as his inhibitor titer only 
reached 146 BU afterwards. The reason his anamnestic response differed between 
these two exposures to exogenous cFVIII is unknown, but suggests that by the second 
exposure the suppressive mechanism behind the decline in his inhibitor titer had 
eliminated enough of the B and T cells driving inhibitor production to control the 
anamnestic response more effectively.  
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Figure 3.6: Anti-cFVIII antibody response and cFVIII antigen levels after liver 
delivery of AAV8-hAAT-cFVIII-ΔF in Noah, a novel model of severe HA caused by a 
large gene deletion with high-titer pre-existing inhibitors. Noah received 6.0 x 1012 
vg/kg of AAV8-hAAT-cFVIII-ΔF via peripheral venous administration. (A) Anti-cFVIII 
antibodies were measured by anti-cFVIII IgG1 or IgG2 ELISAs, or by Bethesda assay. 
(B) cFVIII antigen levels were quantified via specific cFVIII ELISA kit. Red arrows 
indicate treatment with exogenous cFVIII.  
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 Unfortunately, Noah died due to bleeding before his inhibitor resolved. However, 
there is good reason to suspect Noah would eventually have eradicated his inhibitor, due 
to his comparatively low inhibitor titer at his last sample (day 741 post vector 
administration), which showed an inhibitor titer of 72 BU. While still high titer, this is less 
than 10% of his peak of 774 BU. In addition, his small anamnestic response after his 
surgery compared to his very large response after his bleed into his chest cavity implies 
that he was becoming less able to respond to cFVIII. His anti-cFVIII IgG1 and IgG2 
levels were also declining significantly and consistently throughout this period. 
Interestingly, his initial levels of anti-cFVIII IgG1 were significantly higher than his anti-
cFVIII IgG2 levels, which has not been our experience118,180; typically, IgG1 against the 
clotting factor is undetectable or at very low levels compared to IgG2. This different 
distribution between IgG subclasses may be simply because he had such a strong 
immune response, but it may also be related to his underlying mutation or other genetic 
factors. Further experiments as this model is expanded will prove very interesting and 
may shed light on this question. We will likely need larger stocks of bypassing agents to 
control bleeding in these experiments, but in the absence of fatal bleeding events we 
hypothesize that immune tolerance can be induced even in the face of very high titer 
inhibitors and an underlying mutation that heavily predisposes the dog to inhibitor 
formation. The dramatic reduction in titer from his peak is unprecedented in such a high-
responding dog and gives us cautious optimism that if bleeding can be controlled in the 
future, similar dogs that mimic the worst-case clinical situation could be tolerized to 
cFVIII. 
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 To better understand how the antibody response in Noah corresponds to the 
inhibitor response observed in patients, which typically involves antibodies to the A2 and 
C2 regions244-247, we used a partial cFVIII peptide library to identify reactive epitopes. 
The peptide library excluded most of the B domain, as our cFVIII construct only contains 
small portions of the B domain and inhibitors that bind the B domain are extremely 
rare274. Figure 3.7 shows Noah’s baseline IgG2 epitope coverage. Interestingly, while 
A2 and C2 are certainly represented, as we would predict from the available patient 
data, A1 and C1 are both more strongly represented by total binding to peptides. Of 
note, the A3 domain is almost completely negative for binding, and the B domain has 
some positive peptides despite only being partially included in the library. This is not 
entirely unexpected, as there are certainly reports of antibodies binding to the B domain, 
and when Noah received plasma to treat bleeding events, he would have been exposed 
to cFVIII-WT that included the B domain. These B-domain-binding antibodies would 
likely shorten the half-life of any infused cFVIII-WT protein but would not be expected to 
inhibit cFVIII function, as the B domain is cleaved off during FVIII activation.  
 
 One caveat when interpreting these results is that the ELISA cannot measure the 
effect of the antibody binding to the peptide; that is, it cannot discriminate between 
inhibitory and non-inhibitory antibodies. Therefore, we cannot say whether the A1 and 
C1 domains are more highly represented in the inhibitor response in this model using 
this method, only that we observed higher levels of total IgG2 binding to peptides from 
these domains. In addition, peptides do not fully recapitulate the conformations seen in 
the full protein and will lack post-translational modifications that may be important for 
antibody binding or function. Linear peptides may thus exclude important conformation-
dependent epitopes, including any that consist of non-adjacent amino acids, or rely on 
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specific modifications. Nevertheless, this method allows us to assess some of the 
diversity of the anti-cFVIII IgG2 response and make some comparisons to the published 
patient data.  
 
One interesting future step would be to examine the baseline epitopes over time 
and see how the response changes during the course of the reduction in anti-cFVIII 
IgG2 levels. We hypothesize that the IgG2 levels against non-B domain peptides would 
decrease more quickly than IgG2 that binds to the B domain, as the B domain is not 
expressed endogenously as part of the transgene cassette, and thus should not undergo 
the same immune tolerogenic process. However, in the absence of exposure to the B 
domain, we would expect some decline in anti-cFVIII B domain titers due to the lack of B 
cell stimulation. 
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Figure 3.7: Epitope diversity of Noah’s baseline IgG2 response to cFVIII. Peptide 
pools covering cFVIII were used to capture cFVIII-specific antibodies. Positive pools 
were broken out into individual peptides, which were all subsequently tested for 
reactivity. (A) The ODs of all peptides in a domain of cFVIII were summed and displayed 
here. (B) Individual ODs for positive peptides.  
70 
 
 
Model 2: Loxley 
 The second novel model was a privately-owned dog named Loxley. Loxley was a 
French bulldog with an intron-22 inversion and < 1% cFVIII antigen and activity. At 
screening for anti-AAV8 NAbs, Loxley did not have an inhibitor to cFVIII, but in the five 
months between screening and vector administration, Loxley developed an inhibitor after 
receiving transfusions to control bleeding. Like Noah, he received 6.0 x 1012 vg/kg of 
AAV8-hAAT-cFVIII-ΔF vector and received rcFVIII protein prior to vector administration. 
His baseline titer was 21 BU, and his peak at day 33 was 46 BU (Figure 3.8B). Due to 
the logistical difficulties of getting samples from privately-owned dogs, day 33 was the 
first sample we were able to obtain after vector administration; thus, we were unable to 
observe most of the period where an anamnestic response is likely to occur, and it is 
likely that his actual peak titer was higher than 46 BU. However, by day 769, Loxley had 
eradicated his inhibitor (Figure 3.8B) and was expressing 2.2% cFVIII activity (Figure 
3.8A), sufficient to convert him to a moderate HA phenotype. He still had circulating anti-
cFVIII IgG2 antibodies, which likely shortened the half-life of the endogenous cFVIII, as 
in other dogs we have observed progressive factor increases to a plateau level that 
correlate inversely with anti-factor antibodies118,180. Despite the 2.2% endogenous cFVIII 
activity, Loxley died after a bleed into his spinal cord from an unknown cause. However, 
he was successful at eradicating his inhibitor and, given the successes in other dogs, 
would likely have eradicated his remaining antibodies and achieved complete immune 
tolerance to cFVIII.  
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Figure 3.8: cFVIII activity and anti-cFVIII antibody response after liver delivery of 
AAV8-hAAT-cFVIII-ΔF delivery in Loxley, a novel model of severe hemophilia A 
with pre-existing high-titer inhibitors. Loxley received 6.0 x 1012 vg/kg of AAV8-hAAT-
cFVIII-ΔF vector via peripheral venous injection. (A) cFVIII activity was measured by 
chromogenic FVIII assay. Dashed line indicates 1% cFVIII activity, the cutoff for a severe 
phenotype. (B) Anti-cFVIII antibodies were quantified by anti-cFVIII IgG2 ELISA or by 
Bethesda assay.  
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Model 3: Texas trio 
 The last novel model consists of three brothers (T01, T02, and T03) that were 
also originally privately-owned dogs who developed inhibitors and were donated to the 
dog colony at UNC-CH. Their underlying mutation is also an intron-22 inversion, and the 
fact that all three dogs developed high titer inhibitors after treatments with plasma for 
bleeding suggests that there are other genetic factors in their family that predispose 
them to develop inhibitors, much as family history of inhibitors in patients increases the 
risk of inhibitor development78,82,83. T01 and T02 served as our high-antigen cohort and 
both received 9.0 x 1012 vg/kg of an AAV8-hAAT-cFVIII-ΔF+V3 vector (Figure 3.9), while 
T03 was not treated and served as a control (Figure 3.10). T01 and T02 both received 
approximately 100cc of FVIII-deficient plasma at the time of vector administration.  
 
As Figure 3.9A and 3.9B show, T01 and T02 had inhibitor titers of 107 and 89 
BU at vector administration (respectively), thus putting them well above the 10 BU 
boundary associated with ITI success88. Nevertheless, both dogs have cleared their 
inhibitors and are expressing therapeutic levels of cFVIII activity (Figure 3.9C). 
Remarkably, T01 was inhibitor-free after only 113 days, much more quickly than high-
titer inhibitor patients who tolerize under ITI protocols, and this is true despite a bleed on 
day 49 that was treated with rcFVIII. T01 did not have any detectable anamnestic 
response after vector administration, nor did he respond negatively to the infused rcFVIII 
for his bleed. His anti-cFVIII IgG1 levels declined to background levels by day 140, and 
his anti-cFVIII IgG2 reached background around day 226, when he had 5.4% cFVIII 
activity (Figure 3.9C). Since then, his cFVIII levels have slowly increased, suggesting 
that there may be some circulating antibodies our assays cannot detect but still 
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decrease the half-life of the endogenously produced cFVIII. His latest sample reached 
9.0% cFVIII activity, thus converting him from a severe HA phenotype with high-titer 
inhibitors to an inhibitor-free mild phenotype in a relatively short timeframe.  
 
74 
 
 
Figure 3.9: Anti-cFVIII antibody responses and cFVIII activity in two dogs with 
severe hemophilia A on a novel genetic background and pre-existing high-titer 
inhibitors after liver delivery of AAV8-hAAT-cFVIII-ΔF+V3. T01 (A and C [blue]) and 
T01 
T02 
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T02 (B and C [green]) received 9.0 x 1012 vg/kg of AAV8-hAAT-cFVIII-ΔF+V3 via 
peripheral venous injection. (A, B) Anti-cFVIII antibodies were measured via specific 
anti-cFVIII IgG1 or IgG2 ELISAs, or by Bethesda assay. Red arrows indicate 
administration of rcFVIII to control bleeding. (C) cFVIII activity was quantified by 
chromogenic assay.  
 
 
 
 
 
Figure 3.10: Anti-cFVIII antibody responses in a hemophilia A dog with pre-
existing high-titer inhibitors and a novel genetic background that did not receive 
vector. Anti-cFVIII antibodies in T03, the littermate of T01 and T02 who did not receive 
gene therapy, were measured by anti-cFVIII IgG1 or IgG2 ELISAs, or by Bethesda 
assay. Horizontal axis represents days of observation since arrival at the dog colony. 
Blue arrows indicate the use of recombinant human FVIIa to treat a bleed. Red arrows 
indicate a bleeding event and the use of anti-fibrinolytic agents to treat it. 
 
 T02 has also eradicated his inhibitors, but still has detectable anti-cFVIII IgG2 
after 458 days after vector administration (Figure 3.9B). His first inhibitor-negative time 
point was at day 352, although there was cFVIII activity > 1% by day 270 (Figure 3.9C). 
Unlike his brother T01, he had a large anamnestic response after vector administration, 
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with a peak titer of 182 BU at day 14, more than double his baseline titer. It is unknown 
why he and his littermate differed so dramatically in their responses to the vector, but 
there is also significant variation in patient responses to ITI88,92. It is interesting that T02’s 
peak titer was nearly double T01’s, and yet it took him nearly three times as long to 
eradicate it. Nevertheless, his peak titer was nearly as high as Wembley’s (Figure 3.3B) 
yet he took only approximately 64% as long to tolerize. T02 has not been exposed to 
exogenous cFVIII since before vector was administered. His most recent cFVIII activity 
level was 2.2%, which corresponds to a moderate phenotype, but given that anti-cFVIII 
antibodies remain at the moment, we expect his levels to increase over time as the anti-
cFVIII IgG is eradicated.  
 
 T03, the untreated littermate of T01 and T02, had a neurological problem 
unrelated to bleeding when he arrived at the dog colony. We wanted to wait until he was 
fully recovered from this before administering vector. As expected from an untreated HA 
dog with an intron-22 inversion, cFVIII antigen and activity were undetectable in T03 at 
all time points. Patients with high-titer inhibitors often see a gradual reduction in inhibitor 
titer over time if they are not exposed to FVIII. Similarly, T03 was not exposed to cFVIII 
during the monitoring period in Figure 3.10, and also saw reductions in inhibitor titer and 
anti-cFVIII IgG2 and IgG1 over time, thus supporting the relevance of this model of high-
titer inhibitors to patient experiences. Like patients with high-titer inhibitors, he was 
treated with bypassing agents such as hFVIIa and anti-fibrinolytic drugs for bleeding. By 
day 147 of monitoring, T03 still had an inhibitor titer of 73 BU, compared to 0 BU and 21 
BU in his treated brothers T01 and T02, respectively. On T02's first inhibitor-negative 
day, T03's inhibitor titer was still 35 BU, despite approximately 1 year without any 
exposure to cFVIII. Inhibitor titer < 10 BU at the start of ITI is associated with success88, 
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T03 never reached this threshold despite nearly 500 days of cFVIII-free observation. 
T03's persistent high-titer inhibitor recapitulates the clinical experience with high-titer 
inhibitors, as they take substantial amounts of time to decline even without exposure to 
FVIII. In addition, the endogenously expressed cFVIII in T01 and T02 was able to 
eradicate high-titer inhibitors, while T03 still had circulating high-titer inhibitors despite a 
total lack of exposure to cFVIII. These results further support the use of liver-directed 
gene therapy to eradicate high-titer inhibitors, even those above the 10 BU threshold 
correlated with ITI success. 
 
Kinetics of inhibitor eradication 
 We observed that the inhibitor titers in dogs with pre-existing high-titer inhibitors 
tended to follow a nonlinear decline; the decline from peak was much faster than the 
decline at later time points. In fact, when we took the inhibitor titers of T01, T02, and 
Wembley at or after the peak titer – regardless of whether there was an anamnestic 
response – and fit them to a single-phase exponential decay function, we observed an 
excellent correlation (Figure 3.11). Similar analysis was not feasible in Noah, due to his 
multiple exposures to exogenous cFVIII and subsequent anamnestic responses, nor in 
Loxley, due to the limited number of samples. A decline in inhibitor titer in the presence 
of cFVIII must be a result of both loss of cFVIII-specific B cells and removal of inhibitory 
antibodies from circulation. From this, one might hypothesize that a two-phase function 
would more accurately represent the system. Interestingly, the fit did not substantially 
improve when a two-phase exponential decay function was used instead (Figure 3.12), 
suggesting that the half-life parameter (Table 3.3) is either dominated by a single 
function or that the two parameters have such similar time scales that they can be 
accurately approximated by a single time function. Given that the half-lives of these 
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functions vary > 2-fold between these three dogs, and that the normal half-life of IgG in 
circulation should not exhibit this variance, we suggest that the half-life of the inhibitor-
producing plasma cells dominates the time function in this mathematical model. While it 
is possible that the different levels of cFVIII production from the vector between dogs 
could alter the circulating half-life of the cFVIII-specific IgG enough to account for 
discrepancies between dogs, it would seem unlikely that the various cFVIII levels could 
alter IgG half-life in circulation to so closely match the plasma cell half-life.  
 
 Despite the differences in the kinetics of inhibitor eradication, all of the dogs with 
inhibitors to cFVIII either eliminated their inhibitors completely or reduced titers by >90% 
(before dying from spontaneous bleeding prior to study completion). We used three 
separate approaches to express FVIII protein from the livers of these dogs; 1) the high-
dose dual-vector approach in K01, K03, L44, and Wembley, 2) the low vector dose 
expressing cFVIII-ΔF in Noah and Loxley, and 3) the intermediate vector dose 
expressing cFVIII-ΔF+V3 in T01 and T02. All three approaches were successful. Indeed, 
at least one dog in each approach was able to eradicate pre-existing inhibitors, 
regardless of vector dose. Combined, these data support the hypothesis that the 
continuous, uninterrupted expression of FVIII achieved by AAV gene transfer is sufficient 
to induce antigen-specific immune tolerance.  
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Figure 3.11: Inhibitor titers at or after the peak response following liver 
administration of AAV8-cFVIII fitted to a single-phase exponential decay function. 
Anti-cFVIII inhibitor titers of T01 (A), T02 (B), and Wembley (C) were measured by 
Bethesda assay and fitted to a single-phase exponential decay function with the plateau 
value constrained to zero. All dogs received AAV8-cFVIII via peripheral venous injection 
as described previously.  
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Table 3.3. Characteristics of single-phase and two-phase decay fitting to inhibitor 
titer in dogs with severe hemophilia A and pre-existing high-titer inhibitors after 
liver delivery of AAV8-cFVIII. 
   Single-phase decay Two-phase decay 
Dog Peak 
titer, BU 
cFVIII 
activity, % 
Half-life 
(days) 
Fit, R
2 
Half-life 
1 (days) 
Half-life 
2 (days) 
Fit, R
2 
T01 107 9.0* 17.3 0.9706 17.3 13.8 0.9706 
T02 182 2.2* 43.0 0.9614 51.8 7.2 0.9733 
Wembley 217 6.0 38.1 0.9927 93.2 22.3 0.9994 
*, plateau not yet determined 
81 
 
 
Figure 3.12: Inhibitor titers at or after the peak response following liver 
administration of AAV8-cFVIII fitted to a two-phase exponential decay function. 
Anti-cFVIII inhibitor titers of T01 (A), T02 (B), and Wembley (C) were measured by 
Bethesda assay and fitted to a two-phase exponential decay function with the plateau 
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value constrained to zero. All dogs received AAV8-cFVIII via peripheral venous injection 
as described previously. 
 
IV. Discussion 
 
 These results provide crucial support for our previous work showing immune 
tolerance induction in dogs with severe hemophilia A and pre-existing inhibitors. 
Continuous, uninterrupted antigen expression was able to induce antigen-specific 
immune tolerance in novel outbred dog models of severe HA and in one dog exposed to 
hFVIII xenoprotein. Differences in the antigen levels we achieved or the vector doses we 
used did not seem to affect the ultimate success rate. This work also provides crucial 
support for the use of minor modifications to FVIII, like the furin deletion (ΔF) or the V3 
peptide, in inducing immune tolerance. These modifications are not just useful for 
increasing hemostatic efficacy at lower vector doses in naïve dogs but can also be used 
effectively in settings where a pre-existing inhibitor response exists, even if those 
inhibitor titers are much higher than the cutoff predictor for positive ITI success (10 
BU88). After inhibitor eradication, the sustained cFVIII expression from the vector acts 
like a simplified version of the secondary prophylactic replacement protocols that are 
believed to reduce risk of relapse after successful inhibitor eradication in ITI. Long-term 
follow-up on a dog exposed to hFVIII xenoprotein showed induction of cFVIII-specific 
immune tolerance and therapeutic levels of expression more than six years after gene 
transfer that were stable upon rcFVIII protein immunologic challenges. We observed 
total eradication of inhibitors and detectable non-neutralizing antibodies in one dog, and 
inhibitor eradication and a decline in total anti-cFVIII antibodies in two others. Once all 
anti-cFVIII antibodies are undetectable, the next step would be verifying the 
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pharmacokinetic properties of infused cFVIII and performing immunologic challenges 
with cFVIII to confirm complete immune tolerance as per the ITI criteria.  
 
While the exact mechanism for success in ITI is unclear in humans, the general 
concept is that repeated exposure to FVIII causes a down-modulation of the FVIII-
specific antibody response and results in the induction of immune tolerance104,105. 
Preclinical models showed that the response depends on both B and T cells100-102, as 
would be expected. The mechanism behind the immune tolerance induction reported 
here is unknown. Previous work in both mice and non-human primates showed that 
continuous AAV-mediated expression from the liver can induce antigen-specific immune 
tolerance, and that this process is dependent on regulatory T cells177,181,193. Our previous 
work showed a transient upregulation of regulatory T cells after gene transfer180,194 in our 
hemophilia A dog models, and dog models of hemophilia B exhibited cytokine profiles 
consistent with regulatory T cell involvement after vector administration118,194. However, 
the function, Treg subset, and antigen specificity of these cells remain to be determined. 
In addition, the B cell compartment will likely be an important part of the immune 
tolerance induction mechanism and should be investigated. We are currently developing 
methods to better understand and evaluate the function, Treg subset, and antigen 
specificity of the Treg cells, as well as the B cell compartment.  
 
 These four dogs in our novel models of severe canine HA substantially expand 
our experience with using liver-directed gene therapy to induce immune tolerance. Direct 
comparisons between these dogs and with our previous results are difficult to make, due 
to the use of different vectors at different doses and the differences in underlying 
mutation, genetic background, and inhibitor titer, but two observations in particular stood 
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out as worthy of discussion. First, antigen levels may positively correlate with rate of 
inhibitor eradication. While we do not yet have plateau antigen levels in any of these 
newly reported dogs, we administered higher vector doses to T01 and T02 than we did 
to Noah and Loxley, and the vector T01 and T02 received was expressing a FVIII variant 
that resulted in higher levels of circulating FVIII antigen in mice (Figure 3.4). As a result, 
we expect that the plateau antigen levels in T01 and T02 would be higher than the 
plateau levels in Noah and Loxley. T01 and T02 also eliminated their inhibitors much 
more quickly than Loxley did, and although Noah’s titer dropped by >90% from his peak 
value, he still had circulating high-titer inhibitors when he had his fatal bleeding event. 
This bleed occurred more than twice as many days after vector administration as T02 
took to reach a negative inhibitor titer. However, caution must be used when interpreting 
these results, as Noah had a much higher inhibitor titer at baseline, a more provocative 
underlying mutation, and was exposed to exogenous cFVIII during two separate 
bleeding events. On the other hand, Loxley had a lower inhibitor titer at vector 
administration, the same underlying mutation as T01 and T02, albeit on a different 
genetic background, was not exposed to cFVIII during bleeding events, and his inhibitor 
titer still took more than twice as long as T02’s did to disappear. Therefore, there is 
perhaps a trend towards higher antigen levels resulting in more rapid eradication of 
inhibitors, but further research with more easily comparable groups will be needed 
before firm conclusions can be drawn.  
 
 Ultimately, despite the effects of antigen on the kinetics, all dogs either achieved 
immune tolerance or reduced their antibody titers by > 90% of peak. The continuous 
expression of the transgene differs from the clinical ITI experience, as there is no 
possibility of patient non-compliance (e.g. missing doses, pausing due to complications 
85 
 
in the central line, etc.). We believe this likely contributes to gene therapy's ability to 
induce immune tolerance to the transgene in these models at a much higher success 
rate than the clinical ITI experience (~60%).  
 
The second interesting observation is that anamnestic responses to cFVIII 
seemed to prolong the time to inhibitor eradication, but did not affect the success rate, 
contrary to clinical experiences with protein-based ITI. The dogs with high-titer inhibitors 
at baseline were all above the 10 BU threshold associated with poor outcomes in ITI88, 
but were still able to either completely eradicate their inhibitors or reduce them by >90% 
of the peak value. In clinical practice, it is common to wait to start ITI until the inhibitor 
titer drops below 10 BU, which is a good prognostic factor for successful immune 
tolerance. Our results indicate that the thresholds observed in protein-based ITI may not 
apply to gene therapy-based ITI. In addition, Noah and Wembley both had a peak 
anamnestic response of >200 BU, which is also associated with lack of success in ITI88, 
but still tolerized or substantially reduced their inhibitor titer.  
 
Anamnestic responses seem to prolong the time to inhibitor eradication. T02 had 
an anamnestic response and took about three times as long to eliminate his inhibitors 
compared to T01, who had no anamnestic response and received the same vector at the 
same dose. Noah and Loxley both had anamnestic responses as well, whether to the 
cFVIII expression from the vector or from the exogenous cFVIII co-administration with 
vector, and similarly took substantially longer to eradicate or dramatically reduce their 
inhibitor titer. Both dogs that received exogenous cFVIII protein had an anamnestic 
response, while one of two dogs that did not receive exogenous cFVIII developed a 
response. Confounding interpretation of these results are the factors discussed 
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previously, but there may be a trend towards anamnestic responses prolonging time to 
inhibitor eradication. Administration of exogenous FVIII to attempt to enhance vector 
transduction may therefore have to be balanced against the likelihood of an anamnestic 
response to the protein. As with the possible trend towards more rapid eradication of 
inhibitors resulting from higher antigen levels, additional research with fewer 
confounding factors may prove to be highly informative.   
 
 Vector administration was well-tolerated, with no abnormalities on serial 
determinations of hematologic and biochemical analyses of blood and serum samples 
for liver and kidney function. As a single injection, vector administration was also much 
less challenging than administering high-dose factor every day or every other day, as 
would be required for ITI. It has provided long-term clinical benefit after inhibitors were 
eradicated, by providing therapeutic levels of cFVIII even while non-neutralizing 
antibodies were still in circulation. Therefore, liver-directed gene therapy offers patients a 
promising and attractive alternative to ITI and secondary protein replacement therapy 
prophylaxis, in terms of convenience, quality of life, and efficacy. Indeed, these results 
may have relevance beyond hemophilia, including a wide variety of diseases where 
formation of antibodies to the therapeutic protein prevent or inhibit optimal treatment with 
a protein drug275-277. 
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CHAPTER 4 – Conclusions and future directions 
 
 Gene therapy as a field is experiencing a renaissance after previous setbacks, 
notably the death of Jesse Gelsinger in 1999 and the leukemia induced by retroviral 
vectors in the early 2000s. Recently, the FDA approved Luxturna™, the first AAV-based 
gene therapy approved in the US, and several CAR T cell therapies to treat various 
hematologic cancers. AAV alone has been used in more than 150 past, present, or 
planned clinical trials278 for a wide variety of disease and target tissue applications using 
distinct vectors. There have been promising results in hemophilia A233,234 and B16, β-
thalassemia279, sickle cell disease280, spinal muscular atrophy264, and of course many 
different cancers via CAR T cell therapy4. Based on these promising clinical results, it is 
expected that the number of gene therapy products in the US and EU will expand rapidly 
in the near future.  
 
 Immune responses to gene transfer pose large potential safety and efficacy 
concerns for the field of gene therapy. Hemophilia A and B share a common bleeding 
phenotype, but differ substantially in their likelihood of an immune response to protein 
replacement therapy65,67 and some of the additional complications of the antibody 
responses68,93,95. This work, using these immunologically distinct diseases, has shown 
that gene therapy can both prevent immune responses in naïve, inhibitor-prone large 
animal models (Chapter 2), but also to reverse pre-existing antibody responses even in 
very provocative models (Chapter 3). The continuous, uninterrupted expression resulting 
from gene therapy targeted to distinct tissues appears to recreate the normal 
phenomenon of peripheral immune tolerance. Thus, hemophilia B patients with a wide 
range of underlying F9 mutations currently excluded from liver-directed gene therapy 
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clinical trials due to iatrogenic liver disease could have some of their unmet needs 
addressed with skeletal muscle-directed gene therapy. In addition, hemophilia A patients 
excluded from gene therapy clinical trials on the basis of current or past inhibitors could 
be treated with liver-directed gene therapy to induce immune tolerance to FVIII and 
provide secondary prophylaxis after inhibitors are eradicated.  
 
 We hypothesize that there are at least two important factors that increase the 
ability of gene therapy to induce antigen-specific immune tolerance relative to protein-
based ITI. First, gene therapy results in stable and uninterrupted levels of antigen, and 
second, endogenous antigen production likely provides more exposure to tissue-resident 
immune cells. Regular protein infusions, either for prophylactic factor replacement or for 
ITI, result in low trough levels and gaps in antigen exposure to the immune system 
(Figure 4.1). Additionally, patient compliance with prophylaxis or ITI is not perfect, which 
results in even longer gaps in antigen exposure. Production of antigen from cells in the 
target tissue likely recapitulates the normal process of peripheral immune tolerance via 
exposure to tissue-resident immune cells more so than simple exposure to antigen 
through the vascular system. Combined, these properties may help explain the ability of 
gene therapy targeting different tissues to induce immune tolerance to the therapeutic 
transgene. 
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Figure 4.1: Schematic comparing gene therapy ITI and protein-based ITI. Adapted 
from6. Black dotted line indicates inhibitor titer, green line is factor activity and blue line is 
factor antigen level.  
 
Skeletal muscle-directed gene therapy, hemophilia, and immune tolerance 
 The first clinical use of AAV in skeletal muscle was in a gene therapy trial for 
hemophilia B112,281. Since then, the clinical focus has been on liver-directed gene therapy 
trials, due to the dose advantage it had over intramuscular administration to skeletal 
muscle. However, these trials exclude a substantial proportion of relatively older people 
with hemophilia B due to liver disease, which is often iatrogenic. These patients have 
significant unmet need that liver-directed gene therapy cannot solve. Chapter 2 
demonstrates more effective and safe methods of delivering AAV vector to skeletal 
muscle, which resulted in a dramatic reduction of the dose advantage. Indeed, at doses 
used in clinical trials, curative levels of FIX activity were achieved via the use of 
peripheral transvenular vector delivery to an isolated limb and the FIX-R338L (Padua) 
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variant, which has shown excellent safety in both preclinical114,118 and clinical16 studies. 
Despite FIX-Padua's increased specific activity relative to FIX-WT, it has not been 
associated with any thrombogenic safety concerns in those studies or this work. These 
results support the safety and efficacy of ongoing gene therapy clinical trials utilizing 
FIX-Padua.  
 
 Importantly, FIX-Padua has also been demonstrated to induce immune tolerance 
to FIX in one dog with pre-existing inhibitors118 after liver-directed gene transfer. It has 
also not exhibited increased immunogenicity relative to FIX-WT in the liver of inhibitor-
prone dogs or the skeletal muscle of UNC-CH dogs. The mechanism behind this 
induction of immune tolerance induction is currently unknown; however, there are recent 
reports of muscle-resident T regulatory cells282 that may play a role. Future studies 
examining this possibility would be very interesting, although highly technically 
challenging. We hypothesize that the continuous, uninterrupted expression of the 
transgene induces immune tolerance; it would therefore be of great interest to examine 
whether skeletal muscle-directed gene therapy can reverse a pre-existing immune 
response, as we have observed after liver-directed gene therapy118,180.  
 
 Chapter 2 provides evidence in the most provocative model of skeletal muscle 
gene therapy that FIX-Padua is not more immunogenic than FIX-WT and is effective at 
inducing immune tolerance to FIX-WT protein replacement therapy. All liver-directed 
gene therapy trials for hemophilia B have used steroids in at least one patient or have 
lost expression due to the anti-AAV capsid-induced cytotoxic T cell response28, even at 
low vector doses. Therefore, it seems immunosuppression of some sort may be required 
in at least a percentage of the patient population, regardless of target tissue or route of 
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administration. Cyclophosphamide was used here due to our previous experiences and 
its lack of toxicity, but we will gain further experience with immunosuppression in 
muscle-directed gene transfer for other muscle-target diseases, such as Duchenne 
muscular dystrophy or spinal muscular atrophy, and will be able to refine the 
immunosuppressive protocol accordingly.  
 
 Chapter 2 provides additional support for the use of transgenes that have been 
modified to improve their efficacy, such as FIX-Padua, in skeletal muscle-directed gene 
therapy. The curative levels of FIX activity could not have been achieved with FIX-WT at 
this vector dose, and new hyperactive FIX variants beyond FIX-Padua may be even 
more efficacious. However, additional changes to the protein sequence may result in 
increased immunogenicity, and they must be rigorously tested for safety. As hemophilia 
A is more common, and thus has more patients with underlying liver disease, an 
interesting next step would be applying the skeletal muscle gene therapy approach to 
hemophilia A. Ongoing studies in our lab are focusing on developing smaller, highly 
active promoters to efficiently package the FVIII sequence and other necessary 
elements into an AAV vector targeted to skeletal muscle, and immunogenicity may be a 
larger concern due to the higher rate of inhibitor formation in hemophilia A . However, 
skeletal muscle-directed gene therapy and its ability to induce immune tolerance to 
protein replacement therapy may not be limited to applications in hemophilia and 
diseases of the muscle. It may be an attractive platform for other diseases that require 
secretion of a therapeutic protein into the circulation, like Pompe disease283, Fabry 
disease283, or the mucopolysaccharidose family of inherited lysosomal storage 
disorders284.  
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Liver-directed gene therapy, hemophilia, and reversal of an existing immune 
response 
 We and others have previously shown the ability of liver-directed gene therapy to 
reverse a pre-existing immune response118,177-180. Chapter 3 further supports this 
hypothesis in novel dog models of severe hemophilia A with pre-existing high-titer 
inhibitors. Importantly, expression of the cFVIII-ΔF+V3 variant protein from the liver was 
able to eradicate high-titer inhibitors in both dogs, suggesting that small modifications in 
the B domain may facilitate the induction of immune tolerance. We believe this adds to 
the evidence120 supporting the use of hFVIII-ΔF in gene therapy clinical trials, in patients 
with or without inhibitors. This study also supports the inclusion of patients with inhibitors 
in liver-directed gene therapy trials, as liver-directed gene therapy appears to 
recapitulate the immune tolerance-inducing effects of ITI with just one administration of 
vector. Patients with high-titer inhibitors, especially those who are refractory to ITI, have 
substantial unmet need, and liver-directed gene therapy seems poised to address it. 
There are open questions regarding the impact of antigen levels on the kinetics of 
immune tolerance induction; our results suggest that, as in protein-based ITI, higher 
antigen levels increase the rate of inhibitor eradication, but the continuous expression is 
what ultimately drives successful immune tolerance induction.  
 
 The ability of liver-directed gene therapy to reverse a pre-existing immune 
response or prevent a new immune response could benefit patients well outside of 
hemophilia. There are many genetic diseases treated with protein replacement therapy 
where immune responses against the protein drug are a serious concern, including both 
Pompe and Fabry disease283. Pompe disease seems especially suited to this 
approach285,286, as in one study 85% of patients developed anti-drug antibodies in the 
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absence of significant immunosuppression287, and many patients are dependent on 
enzyme replacement therapy (ERT) for survival288-290. Preclinical work in mice suggested 
that liver-directed gene therapy enhanced the efficacy of ERT and prevented anti-drug 
antibodies291. Even in the event that gene therapy is unable to achieve therapeutic levels 
of enzyme, inducing immune tolerance to ensure ERT is still effective would be a 
substantial improvement for many patients.  
 
 However, the use of liver-directed gene therapy to induce immune tolerance 
need not be restricted even to genetic diseases. People who have autoimmune 
conditions with known autoantigen targets could also benefit from a novel method to 
induce immune tolerance, including some cases of Type I diabetes, autoimmune 
thrombocytopenic purpura, and Addison’s disease. There are, however, two potential 
roadblocks to applying liver-directed gene therapy in this manner. First, some of these 
diseases are caused by cytotoxic T cell responses against a protein, and while liver co-
transplantation with other organs reduces the risk of immune rejection292-294, the potential 
of gene therapy to suppress cytotoxic T cell responses as opposed to humoral 
responses is less well known. In addition, cytotoxic T cell responses could reduce 
transgene expression over time by eliminating transduced cells, making the persistence 
of expression unclear. Second, without a thorough understanding of the mechanism by 
which liver-directed gene therapy induces immune tolerance, its application to 
autoimmune conditions that result from a failure to induce or maintain immune tolerance 
is somewhat uncertain. Nevertheless, as the mechanism is elucidated and the 
parameters for successfully inducing immune tolerance become more well-defined, the 
potential applications for liver-directed gene therapy in autoimmune conditions will 
become clearer.  
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 The mechanism behind this immune tolerance induction is currently unknown. 
Our previous work in dog models of severe hemophilia A180,194 and B118 are consistent 
with the hypothesis that regulatory T cells are involved in the process, but due to 
limitations in the available reagents and the number of animals, the data are not 
definitive. Upregulation of the total regulatory T cell population180,194 and systemic 
cytokine trends consistent with regulatory T cell activity118,194 are suggestive, but further 
defining the phenotype, activity, and antigen specificity of these cells will be paramount 
to understanding the mechanism by which peripheral tolerance is induced. We 
hypothesize that the tolerogenic environment within the liver promotes the conversion of 
CD4+ T cells to pTregs, which suppress antigen-specific antibody production both by 
preventing follicular B cell development and by suppressing long-lived plasma cells. 
Specifically, some of the induced pTregs may receive further stimulation by PD-L1 and 
convert to TFR cells that traffic to the B cell follicles and suppress B cell differentiation via 
their interactions with germinal center B cells139,142-144,146 and follicular helper T cells145. 
Other pTregs likely migrate to the bone marrow and regulate the pre-existing plasma 
cells producing inhibitors via CTLA-4, although whether they directly interact with the 
plasma cells or suppress them indirectly through modulation of the resident dendritic 
cells is not well defined149.  
 
 To test this hypothesis, we would first investigate changes in the peripheral blood 
immune cells via flow cytometry. Specifically, we would examine additional cell markers 
beyond CD4, CD25, and Foxp3 to further define the Treg subset(s) that expanded after 
liver-directed gene transfer in our previous observations180,194. To verify these cells do 
not have a thymic origin, we would examine the proportion of Helios+ cells during 
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expansion compared to baseline. A population of canine CD4+CD25+Foxp3+ cells 
express Helios, suggesting that canine tTregs share this marker with mouse and human 
tTregs295. Therefore, if the expanded population of Tregs are not tTregs, the ratio of 
CD4+CD25+Foxp3+Helios- to CD4+CD25+Foxp3+Helios+ cells should increase after 
gene transfer. Next, we would attempt to validate an antibody against canine CTLA-4. 
CTLA-4 is required for Treg modulation of plasma cells in mice149, but whether it serves 
the same function in dog Tregs is currently unknown. At this stage, during activation or 
conversion to regulatory T cells, CD4+CD25+Foxp3+Helios-CTLA-4+ cells could be 
pTregs or Tr1 cells, if canine Tr1 cells transiently express Foxp3 upon activation as 
human Tr1 cells do161,162. Canine pTregs and Tr1 cells are not well-characterized; 
however, both mouse and human Tr1 cells can be identified by coexpression of CD49b 
and LAG-3165. We hypothesize that our expanded Treg population consists of pTregs; 
accordingly, after validating the CD49b and LAG-3 antibodies, we would not expect to 
observe CD49b and LAG-3 expression in our population of interest. Lastly, to test the 
hypothesis that some pTregs are converting to TFR cells and acting in the B cell follicles 
to suppress further plasma cell differentiation, we would examine whether some 
proportion of our expanded Treg population is expressing Bcl-6 and CXCR5, which are 
necessary for localization to the germinal centers in both mice and humans142. We would 
expect some subpopulation to coexpress these markers, although with small total cell 
numbers it may be difficult to reliably detect subpopulations. Ideally, we would also 
examine the immune cells in lymph nodes and bone marrow within these dogs. 
However, biopsies in dogs with high-titer inhibitors carry a number of logistical 
challenges that may preclude these experiments for the time being.  
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 As dog models of cancer and genetic disease become more widely used296,297, 
and better reagents for canine immunology studies are developed, the ability to 
thoroughly probe these cells will increase. The benefits of a more thorough 
understanding of this mechanism include a better comprehension of the risks and 
rewards of using liver-directed gene therapy to induce immune tolerance, and potentially 
ways to improve current protein-based immune tolerance induction protocols. 
 
Closing remarks 
 Gene therapy is a technology just beginning to realize its potential. From 
providing therapeutic options to patients who had none before, to new and better 
treatments for more common diseases, gene therapy has an incredibly diverse range of 
potential applications. In particular, the ability to reverse immune responses to specific 
antigens while providing simplified protein replacement therapy will likely prove to be a 
powerful tool in the years to come.  
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APPENDIX A – ABBREVIATIONS 
a (suffix): activated 
ApoE: apolipoprotein 
aPTT: activated partial thromboplastin time 
AAV: adeno-associated virus or adeno-associated viral vector 
BDD: B-domain deleted (referring to factor VIII) 
BU: Bethesda Unit(s) 
c (prefix): canine 
CRM: cross-reactive material 
ELISA: enzyme-linked immunosorbent assay 
ERT: enzyme replacement therapy 
F: factor 
h (prefix): human 
HA: hemophilia A 
hAAT: human alpha-1-antitrypsin, or the promoter/enhancer combination of the human 
 alpha-1-antitrypsin promoter and apolipoprotein E enhancers 
HB: hemophilia B 
HC: heavy chain (of factor VIII) 
ITI: immune tolerance induction 
ITR: inverted terminal repeat 
LC: light chain (of factor VIII) 
m (prefix): murine 
NAb: neutralizing antibody 
PBMCs: peripheral blood mononuclear cells 
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PBS: phosphate-buffered saline 
PC: plasma cell 
r (prefix): recombinant 
TAT: thrombin-antithrombin complex 
TBG: human thyroxine binding globulin 
UAB: University of Alabama at Birmingham 
UNC: University of North Carolina 
UNC-CH: University of North Carolina at Chapel Hill 
WBCT: whole blood clotting time 
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APPENDIX B – DOGS 
 
HB dogs 
M55, male from UNC who received 3 x 1012 vg/kg of AAV6-CMV-cFIX-Padua via 
 peripheral transvenular delivery to skeletal muscle in an isolated limb.  
M59, male from UNC who received 3 x 1012 vg/kg of AAV6-CMV-cFIX-Padua via 
 peripheral transvenular delivery to skeletal muscle in an isolated limb. 
N07, male from UNC who received 3 x 1012 vg/kg of AAV6-CMV-cFIX-Padua via 
 peripheral transvenular delivery to skeletal muscle in an isolated limb. 
O04, male from UNC who received 3 x 1012 vg/kg of AAV6-tMCK-cFIX-Padua via 
 peripheral transvenular delivery to skeletal muscle in an isolated limb. 
O20, male from UNC who received 9 x 1011 vg/kg of AAV6-CMV-cFIX-Padua via 
 peripheral transvenular delivery to skeletal muscle in an isolated limb. 
O23, male from UNC who received 3 x 1012 vg/kg of AAV6-c512-cFIX-Padua via 
 peripheral transvenular delivery to skeletal muscle in an isolated limb. 
U04, female inhibitor-prone from UAB who received 3 x 1012 vg/kg of AAV6-CMV-cFIX-
 Padua via peripheral transvenular delivery to skeletal muscle in an isolated limb. 
U05, female inhibitor-prone from UAB who received 3 x 1012 vg/kg of AAV6-CMV-cFIX-
 Padua via peripheral transvenular delivery to skeletal muscle in an isolated limb. 
 
HA dogs 
K01, male from UNC with pre-existing cFVIII inhibitors, received 2.5 x 1013 vg/kg of 
 AAV8-TBG-cFVIII-LC and 2.5 x 1013 vg/kg of AAV8-TBG-cFVIII-HC i.v. 
K03, male from UNC with pre-existing cFVIII inhibitors, received 2.5 x 1013 vg/kg of 
 AAV8-TBG-cFVIII-LC and 2.5 x 1013 vg/kg of AAV8-TBG-cFVIII-HC i.v. 
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L44, male from UNC with pre-existing cFVIII inhibitors, received 2.5 x 1013 vg/kg of 
 AAV8-TBG-cFVIII-LC and 2.5 x 1013 vg/kg of AAV8-TBG-cFVIII-HC i.v. 
Wembley, male from Queen's University with pre-existing hFVIII inhibitors, received 2.5 
 x 1013 vg/kg of AAV8-TBG-cFVIII-LC and 2.5 x 1013 vg/kg of AAV8-TBG-cFVIII-
 HC i.v., large anamnestic response 
Noah, male donated to UNC, novel large F8 gene deletion, very high titer pre-existing 
 cFVIII inhibitors, received 6.0 x 1012 vg/kg of AAV8-hAAT-cFVIII-ΔF i.v., very 
 large anamnestic response, died from bleeding 
Loxley, male that was privately-owned, intron-22 inversion, pre-existing cFVIII inhibitors, 
 received 6.0 x 1012 vg/kg of AAV8-hAAT-cFVIII-ΔF i.v., died from bleeding after 
 inhibitor eradication 
T01, male donated to UNC, intron-22 inversion, pre-existing cFVIII inhibitors, received 
 9.0 x 1012 vg/kg of AAV8-hAAT-cFVIII-ΔF+V3 i.v. 
T02, male donated to UNC, intron-22 inversion, pre-existing cFVIII inhibitors, received 
 9.0 x 1012 vg/kg of AAV8-hAAT-cFVIII-ΔF+V3 i.v. 
T03, male donated to UNC, intron-22 inversion, pre-existing cFVIII inhibitors 
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